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Traumatic brain injury (TBI) mechanism and severity are heterogenous clinically,
resulting in a multitude of physical, cognitive, and behavioral deficits. However,
approximately 80% suffer from milder injuries. Thus, examining pathophysiological
changes associated with mild TBI is imperative for improving clinical translation and
evaluating the efficacy of potential therapeutic strategies. Through this work, we
developed models of TBI, ranging in both injury mechanism and severity, using an
electromagnetic controlled cortical impact (CCI) device. First, we characterized and
optimized a closed head, mild TBI model (DTBI) to determine the clinical translatability
and practicality of producing repeated mild injuries. Interestingly, we determined that
impact speed was highly dependent on both input velocity and depth. Indeed, impact
conditions differed from input parameters, and we suggest researchers characterize closed
head models using CCI devices to ensure data is interpreted based on the true impact
conditions. Additionally, we investigated how impact speeds influenced pathophysiology,
specifically autophagic flux. Our results show that autophagic flux was impaired acutely
in the hippocampus, regardless of impact speed, providing rationale for evaluating
autophagic flux following mild, diffuse impacts. Thus, we continued investigating
pathophysiological changes associated with a spectrum of TBI, including severe CCI,
modified mild TBI (MTBI), and previously characterized DTBI. Following impacts, we

observed distinct differences in gross neuropathology, which corresponded with changes
in the progression of cell death. Indeed, severe CCI resulted in dramatic increases in
oncosis, while mild models differed regarding apoptotic response, suggesting injury
mechanism and severity shift the progression of cell death. Interestingly, each of the three
impact models resulted in impaired autophagic flux, which coincided with changes in
both oncotic and apoptotic cell death. Thus, these results provide evidence that the
pathophysiological mechanisms affiliated with TBI heterogeneity may be linked through
common upstream events, namely impaired autophagic flux and lysosomal dysfunction.
Therefore, therapeutic strategies designed to intervene in the amelioration of these
consequences may alleviate molecular dysfunction, in addition to the cognitive and
behavioral deficits observed following TBI.
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CHAPTER 1: INTRODUCTION
1.1 Traumatic Brain Injury
Adapted from my previously published literature review [1]:
Traumatic brain injury (TBI) is currently the leading cause of injury related morbidity
and mortality worldwide with an estimated global cost of $400 billion annually [2].
Injury severity and mechanism are heterogenous clinically, leading to a multitude of
physical, cognitive, and behavioral outcomes. These outcomes originate from primary
head impact leading to a spread of secondary injury [3]. External forces can be generated
from direct collision impacts or through non-impact situations, including rotational
acceleration of the head or the energy waves produced from blasts (Figure 1.1) [4, 5].
Impacts result from falls, motor vehicle accidents, assault, domestic violence, military
warfare, and even recreational sports including football, soccer, and boxing [3]. These
multiple mechanisms of impact are a primary cause of heterogenous behavioral
outcomes, leading to difficulties in developing diagnostic and prognostic protocols, let
alone effective treatments. Thus, there is still no approved therapy that has shown
efficacy in reducing the long-term secondary effects following TBI.

Collision Impact

Rotational Acceleration

Blast Wave

Figure adapted from Gabriel Peterman

Figure 1.1. Mechanisms of Traumatic Brain Injury. Primary impacts are caused by three
primary mechanisms of impact including collision impacts through direct contact,
rotational acceleration of the head, and energy produced from blast waves.
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TBI patients have a 2–4-fold increase in the risk of developing dementia later in
life, due to even a single instance of TBI followed by a loss of consciousness (LOC) [6].
In conjunction with aging, individuals who have experienced TBI are at increased risk for
developing Alzheimer’s disease, at 2.3 and 4.5 times more likely for moderate and severe
TBI, respectively [7]. Even repeated mild injuries, such as those with retired professional
American football players, have been correlated to long term cognitive deficits. Retired
players who had suffered three or more concussions in their careers had a 5-fold increase
in mild cognitive impairments as compared to their counterparts with no history of
concussions [6]. Additionally, Parkinson’s disease, amyotrophic lateral sclerosis,
Creutzfeldt-Jakob disease, and chronic traumatic encephalopathy (CTE) were also all
found to be associated with the progression of chronic TBI [6]. Due to the association of
TBI with these progressive neurodegenerative diseases, viable treatment options must be
developed with an in-depth knowledge of the injury’s pathophysiology lest the current
therapeutic stalemate continue.
Unfortunately, these differences between patients and their injuries provide a
variety of complications for medical personnel in determining efficient diagnoses and
effective treatments. Current treatment options include surgical and pharmacological
intervention, including relieving intracranial pressure through craniotomy or ameliorating
symptoms following TBI through antidepressants, anticonvulsants, and stimulants [8].
However, none of these methods have shown efficacy in alleviating the long-term deficits
associated with injury [9-11]. Although there has been success in Phase II trials, all
treatments options have failed during larger, multi-center Phase III trials [12]. These
failures have resulted due to a variety of problems during testing for the efficacy of
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treatments. Clinical trials for testing the efficacy of the pharmacological intervention of
progesterone, the glutamate antagonist, CP 101-606, and the antioxidant, Tirilazad, each
resulted in negative outcomes during Phase III trials [11-14]. Researchers postulate that
these failures were the result of suboptimal dosing during Phase II trials suggesting
inadequate delivery into the brain and poor target engagement. Additionally,
heterogeneity between injuries can result in vastly different secondary pathophysiology
requiring in multiple strategies in pharmacological intervention [15, 16]. Other clinical
trials have had similar issues including problems with clinical trial design, lack of
accurate injury phenotyping, and inadequate outcome assessment tools [16]. Challenges
with injury heterogeneity and inadequate outcome assessment tools are capable of being
mitigated with effective classification systems. Classification systems have been
previously constructed for categorizing the injury severity of TBI in humans immediately
following diagnostic exams from medical professionals. Initial methods for classifying
TBI in a clinical setting are efficient, but simplistic in approach, leaving room for error
between different degrees of human injury. However, recent literature has investigated
the most important variables for assessing TBI in hope of improving upon the original
designs to create a more effective classification system [17, 18].
While methods for classifying degrees of injury in humans have advanced, efforts
have also been directed towards developing animal models for TBI to provide an
effective comparison to human injuries [19, 20]. These models have been used to
understand the pathophysiological mechanism for the progression of different degrees of
TBI. Additionally, animal models have aided in the development of potential treatments
for the reduction of oxidative stress, BBB dysfunction and various other biochemical
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impairments [19-21]. Recently, Operation Brain Trauma Therapy (OBTT) was developed
as a multi-center pre-clinical consortium to identify therapies that are beneficial in
alleviating damage from head trauma in animal models [16]. The OBTT makes use of
several animal models in three distinct injury categories, focal, diffuse, and non-impact
injury, creating a broad spectrum of potential pathophysiological outcome [3, 19]. Each
model has unique procedures and outcomes in hopes to provide a sufficient translation to
the variety of head traumas that occur in humans. Through these models, comparisons
can be derived between the various degrees of human injury severity, which will
ultimately lead to improvements in diagnostics and treatment protocols.
Thus, the role of this research is to understand how injury heterogeneity
influences the changes in molecular pathophysiology following TBI. This goal will be
accomplished through three primary aims including: 1) utilize one impact device to
develop and optimize mild TBI animal models to produce injury variability 2) identify
the effects of injury heterogeneity on pathophysiology, and 3) determine how injury
variability influences the mechanisms of pharmacological targets. These results will
provide insight into how the progression of secondary injury differs in animal models
which reflect the heterogeneity observed clinically. Ultimately, this work will elucidate
pathophysiological similarities and differences to optimize strategies for therapeutic
intervention and provide a more rigorous method for assessing their efficacy.
1.2 Clinical Classification of TBI Severity
The severity of a patient's TBI is primarily affiliated with the mechanism and
severity of injury in which the initial applied force is delivered to the head. This force
will drive the secondary progression of damage and can provide valuable insight into the
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overall development of the condition. However, there are several additional variables that
are required to effectively characterize a patient’s level of injury. These factors help
determine the overall injury progression of the individual. While patient’s injuries can
range from mild, presenting with concussive symptoms, to severe, leading to probable
death, the classification methods developed by previous literature have determined the
different categories of human TBI in between these broad outcomes.
1.2.1 Glasgow Coma Scale
Initial analysis for categorizing the behavioral deficits following TBI in a clinical
setting is based on the Glasgow Coma Scale (GCS), originally developed in 1974 [22,
23]. Although the classification criteria for this system was developed nearly 50 years

ago, the system is still regularly used by medical professionals to evaluate the degree of
injury immediately following head trauma. The GCS provides a reference score
calculated following an examination from a medical professional to identify the strength
of a patient’s response in three main areas: eye movement, verbal response, and motor
function (scale shown in Table 1.1.) [22-24]. Each category is scored based on criteria
increasing in cognitive complexity from a score of 1-6. Summing the three scores allows
for a better understanding of a patient’s TBI severity and enhances the ability to explore
the relationships between score and outcome on an academic level. The GCS scoring
system is categorized into three sections: mild, moderate, and severe TBI (Figure 1.2.)
[25]. Mild injuries receive scores ranging from 13-15, where patients experience a LOC
for less than 30 minutes, followed by post-traumatic amnesia (PTA) for up to 24 hours
[26]. In contrast, severe injuries receive scores of 3-8, with an LOC of over 24 hours and
PTA lasting for over 7 days. Most patients suffer from mild TBI, approximately 80%,
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while moderate and severe TBI represent about 10% of the clinical population,
respectively [27]. Concussions are one specific example of mild TBI, when individuals
experience deficits in cognition or behavior. However, even sub-concussive impacts have
resulted in the chronic progression of behavioral deficits seen in neurodegenerative
diseases [28].
Table 1.1. Assessment criteria of the Glasgow Coma Scale used for determining injury
severity in a clinical setting [22-24].
Response 1

2

Eye

None To Pain

Verbal

None

Motor

None

3

4

5

6

To Speech

Spontaneous

N/A

N/A

Oriented

N/A

Incomprehensible Inappropriate Confused
Sounds
Extension
(Decerebrate)

Words

Conversation

Abnormal

Withdrawal

Flexion

(Normal

(Decorticate) Flexion)

Localizes Obeys
Pain

Commands

Figure 1.2. TBI Epidemiology. The Glasgow Coma Scale provides guidelines for
evaluating the severity of injuries in the clinical population. Scores are categorized into
three groups: Mild (13-15), Moderate (9-12), and Severe (3-8). Reproduced with
permission from [25].
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The GCS system has been used for several decades due to its effectiveness in
predicting outcomes of TBI. A study taking place in 1999 showed that outcome
predictions made using this model were accurate 76.3% of the time at admission, 82.5%
preoperatively, 77.1% at 24 hours, 63.3% at 3 days, and 69.7% at 7 days post TBI [29].
Additionally, in 2014, GCS scores obtained following patient’s exams were shown to be
positively correlated with assessments of metabolism, neuroimaging, collected
biomarkers, and prediction of mortality [23]. However, the GCS method suffers from
limitations when predicting severe TBI outcomes. From the 1999 study, 75.8% of the
overall outcome predictions were correct, however, predictions for an outcome of
severely disabled were only correct 12.2% of the time [29]. It is also important to note
that successful predictions for severe TBI (71.2%) were much lower than predictions of
moderate (90%) and mild (92.9%) TBI [30]. Additionally, GCS scores may be impacted
by a variety of circumstances including behavioral changes from drug and alcohol
intoxication, misinterpretation of patients’ responses, and even early medical intervention
such as intubation which can lead to inaccurate assessment from the GCS [31].
Ultimately, GCS has continued to provide value in TBI classification due to its simplicity
and overall efficiency, specifically for triage while stabilizing patients. However, this
method lacks the ability for an ultimate diagnostic report due to external circumstances
and poor predictability for determining differences between moderate and severe TBI
based on the criteria provided in the scoring system.
1.2.2 Mayo Classification of TBI
To build upon the GCS method and provide a more complete classification
system for the evaluation of TBI injuries, in 2007, the Mayo Clinic developed a model
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incorporating a variety of variables including: death, LOC, post-traumatic anterograde
amnesia (PTA), and computed tomography (CT) imaging [17]. Each of these variables
was used to help categorize injuries into three sections ranging from symptomatic
(possible) TBI, mild (probable) TBI and moderate-severe (definite TBI) [17]. Mayo’s
method was able to improve upon the GCS method by utilizing additional details
following a patient’s exam to effectively achieve a diagnosis [17]. Comparisons were
evaluated between Mayo’s classification system to GCS, PTA, and LOC classifications
alone for the evaluation of 1,678 patients [17]. Mayo’s model was shown to identify
additional patients presenting with moderate-severe TBI that other methods classified as
mild due to the lack of additional parameters. Additionally, Mayo’s classification system
was able to provide a category for patients with possible TBI based on symptoms that no
other model was able to establish previously. Over 50% of the patient study fell into this
symptomatic TBI classification, indicating that a large percentage of head trauma may
not result in pronounced cognitive deficits detected by the GCS system. Individuals
experiencing symptoms of TBI from concussions and minor head trauma may still
require medical care, which may have been overseen from previous classification
methods. Unfortunately, Mayo’s system fails to distinguish between moderate and severe
TBI which lacks details for a wide range of treatment possibilities for the medical
community.
1.2.3 Collaborative European NeuroTrauma Effectiveness for Research for TBI
In April of 2020, analysis conducted in the Collaborative European NeuroTrauma
Effectiveness Research for TBI (CENTER-TBI) expanded upon previous models for
evaluating TBI injuries in humans using a wide variety of variables and characteristics
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[18]. Data was collected from 4,509 patients across Europe and categorized into clusters
using a range of five collective “building blocks” that included: demographics, clinical
severity, secondary insults, cause of injury, and imaging characteristics, such as CT
imaging or Magnetic Resonance Imaging (MRI) [18]. Variables were evaluated to
determine strength of significance, where cause of injury remained the most significant
determinant for the condition’s progression, followed by presence of major extracranial
injury, GCS, and imaging characteristics. Following characterization, CENTER-TBI
provided four separate categories for TBI injury in humans including: mild, upper
intermediate, lower intermediate, severe; and identified the likelihood of each respective
outcome using the Glasgow Outcome Scale Extended (GOSE) [18]. The additional
category for dividing moderate TBI is an improvement from previous classification
models, allowing for additional prognostic guidance. The study also established
probabilities for expected behavioral outcomes in each of the categories. The percentage
of patients remaining in their previously affiliated category after resampling was 97.4%,
confirming a 95% confidence interval [18]. Following this study, researchers developed a
prediction model for determining an individual’s functional outcome based on the
variables described previously, along with additional vitals. Researchers applied baseline
admissions characteristics from examinations and a prediction of the prognostic results
for a 6-month mortality time frame was collected. This prediction model represents the
potential growth in the field of TBI classification. Researchers and medical personnel
would be able to determine an individual’s treatment based on a handful of characteristics
capable of being tested upon entry into the hospital following their initial TBI. While
initial results from GCS scores are efficient and useful for providing an assessment for
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the urgency in treating a patient following admission to a medical facility, developing
classification methods based on additional information is necessary to determine the
overall progression of TBI.
1.3 Clinical Classification of TBI Mechanism
1.3.1 Focal TBI
TBI can often be used to describe a broad condition with varying degrees of
damage, however, the causal injuries associated with TBI are categorized into three
distinct forms: focal, diffuse, and non-impact. Focal injuries in the patient population are
created through direct impact forces acting on the skull, which causes compression of the
underlying tissue. Focal injuries include skull fractures, contusions, lacerations,
hemorrhages, and subdural, epidural and intraparenchymal hematomas [32]. Contusions
from focal injuries are often due to penetrating impacts or severe blunt force trauma,
differing from other ailments that may be caused by diffuse injury. Contusions can occur
in two different forms, coup, also known as ipsilateral, or contrecoup contusions [32].
Coup contusions occur below the impact site when the head absorbs impact and
contrecoup contusions occur opposite of the impact site. For example, impact forces
applied to the frontal lobe (hitting head against wall), produce contrecoup contusions near
the occipital lobe. Contusions differ from lacerations simply by the forces causing the
injury, as contusions are caused by direct blunt forces while lacerations are caused by
shearing forces placed upon the tissue [32]. Additionally, contusions are associated with
damage to small blood vessels, while hemorrhaging is associated with bleeding in the
subarachnoid or subdural space. Subarachnoid hemorrhaging may result from either focal
or diffuse injuries but is more often seen in diffuse injuries [15]. Subdural hematomas are
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usually caused by ruptured veins due to quick acceleration and deceleration forces [15]. A
concern with focal injuries is with intracerebral hematomas which can develop over 24
hours following contusions and, specifically, the subset of intracerebral hematomas that
develop with a delayed onset 1 to 3 days after TBI. Delayed intracerebral hematomas are
incredibly dangerous with a mortality rate between 50% to 75% [32].
1.3.2 Diffuse TBI
While focal injuries are particularly dangerous and concerning, special attention
must be paid to diffuse injuries due to the underwhelming sense of urgency following
trauma. Diffuse injuries describe an injury mechanism where rapid acceleration and
deceleration results in semi-independent movements of brain structures due to the
heterogeneous nature of tissue fixation with other structures and the skull, as well as
tissue consistency [33]. This phenomenon is similar to the effect of whiplash following a
traffic vehicle accident where the brain’s inertia continues in the direction of the applied
force, followed by a rapid deceleration against the inner wall of the skull. Directional
movement influences the diffuse injury severity, as lateral movement tends to cause
worse damage than sagittal movement [15]. This movement can result in vascular injury,
brain swelling or edema, and most commonly a diffuse axonal injury (DAI) [15, 32]. DAI
refers to the tearing of axons which, under normal conditions, would remain intact due to
their high elasticity. However, when enough force is applied, the axons can tear or
deform, resulting in permanent and irreversible damage to the fibers of neurons [15, 32].
It is thought that this irreversible damage is caused by an initial swelling of the axon due
to mitochondrial dysfunction leading to the collapse of the microtubular system
throughout the cell, 6 to 12 hours after the initial swelling [15]. However, there are other
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bodies of evidence that argue axonal swelling continues for years after the primary injury
and could potentially contribute to increased disability in some patients [15].
Furthermore, Doppenberg et al. 2004, recommends excluding patients who are diagnosed
with DAI from clinical trials until a proven therapy specifically for DAI is found in
animal models [15]. Figure 1.3. provides both CT (A-F) and MRI (G-I) images of
pathophysiological changes following both focal and diffuse TBI [32]. This figure
highlights the structural differences between focal and diffuse injuries, which is important
to keep in context when discussing the comparisons between animal models of TBI.

Figure 1.3. Clinical examples of focal and diffuse TBI. Examples of structural changes
following Focal and Diffuse TBI represented by CT Imaging (A-F) and MRI (G-I). A, B
and C are of CT images following focal injuries, indicated by the presence of a focal
contusion in A, as well as hematomas in B and C. Figures D, E and F are of CT images
following diffuse injuries, indicated by hemorrhages in D and E, and diffuse swelling in
F. Images G, H and I are of susceptibility weighted MRI images of one patient presenting
with DAI indicated by hemorrhaging in different regions of the brain. Reproduced with
permission from [32].
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1.3.3 Non-Impact TBI
The final mechanism of injury seen in TBI refers to non-impact injuries. Unlike
focal injuries, non-impact TBI implies damage from injuries which did not result from
direct penetrating or blunt force impact with the skull and is typically induced through
alterations in pressure or acceleration/deceleration from the brain inside the skull. The
associated pathophysiological consequences of non-impact injuries are unique due to the
mechanism of impact, but share features observed in both focal and diffuse TBI.
Additionally, clinical presentation of non-impact injuries is typically coupled with focal
and diffuse injuries leading to compounding effects on the pathological outcome. For
example, members of military warfare can often be exposed to blast injuries, in which
multiple mechanisms of injury are acting on the body. These elements include 1) primary
blast injury: blast wave acting on the brain, 2) secondary blast injury: accelerated
projectiles penetrating the skull, 3) tertiary blast injury: acceleration/deceleration effects
acting on the body, and 4) quaternary blast injury: thermal and chemical injuries to the
head following the initial explosion [34]. However, in this section of the review we will
be referring to the primary blast injury only. Blast waves result in accelerated air pressure
which interacts with the head and body creating acceleration or rotation of the head, and
transfer of the kinetic energy from the blast through fluid circulating in the thorax [35,
36]. Acceleration of fluid within the body, results in increased intracranial pressure which

can result in BBB disruption, vasculature damage, edema, and hemorrhaging [34].
Cognitive deficits from blast injuries include headache, fatigue, problems with sleep and
concentration, and even post-traumatic stress disorder, which is one of the behavioral
aspects most relevant to members of the military [36]. Additionally, road traffic incidents,
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as discussed briefly in the diffuse injury section, can produce rapid acceleration and
deceleration of the brain inside the chamber of the skull, producing edema, vascular
injury, and DAI [15, 32, 37].
While there are similarities between focal, diffuse, and non-impact injuries, each
of these types of traumas produce unique pathological outcomes that are specific to
mechanism of injury delivered to the brain. Therefore, animal models must be developed
with an in-depth knowledge of the mechanism of injury to enhance translation between
the pathophysiological consequences seen following animal injury and clinical TBI.
Through these animal models, researchers will be able to develop therapeutic options for
alleviating the conditions presented within each type of TBI.
1.4 TBI Animal Models
Animal models are valuable tools used for providing an effective comparison to a
variety of human conditions. Understanding the mechanism for the progression of various
diseases allows researchers to develop treatment protocols which can be modified prior to
human testing for optimal results. These models have been created for a multitude of
ailments affecting the brain, including TBI [19, 38]. TBI animal models have aided in the
development of potential treatments for the reduction of oxidative stress, improving BBB
permeability, and other various biochemical impairments following TBI [19, 21, 38].
Several models have been developed, sectioned into three distinct categories as seen in
clinical presentations of TBI: focal, diffuse, and non-impact injury [3, 19]. Each of these
models has distinct procedures and outcomes in hopes of providing a sufficient
translation to the variety of situations for which head trauma occurs in
humans. Additionally, several of these models can be manipulated to alter the levels of
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injury severity, leading to a greater understanding of injury progression. Based on these
experiments, comparisons are derived between the various degrees of human injury
severity, which will ultimately lead to improvements in diagnostics and treatment
protocols.
1.4.1 Controlled Cortical Impact
The controlled cortical impact (CCI) model is currently one of the most used and
well characterized models of TBI, due to the model’s reproducibility and specificity
regarding mechanical parameters [39-42] (57-60). CCI models use a pneumatic or
electromagnetic (Figure 1.4.) impact system to deliver a rigid impactor onto the exposed
dura of the animal, following craniectomy [40]. Originally developed in ferrets, the CCI
model has been adapted for a variety of species including mice, rats, swine, and monkeys
[19, 41]. Features of injury include subdural hematoma, subarachnoid hemorrhage, axonal
injury, in addition to cortical contusions and cortical tissue loss which have been shown
in clinical presentations of TBI [40-42]. Primary advantages for using CCI models include
precise automated control over a variety of factors including impactor diameter, velocity,
depth, and dwell time of impact [42]. Previous literature has identified the appropriate
depths for inducing mild, moderate, and severe TBI’s at 0.0-0.2 mm, 0.5-1.0 mm, and
1.2-2.0 mm, respectively [42]. Figure 1.5. shows whole brain images and histological
images of coronal brain slices following a moderate TBI with a velocity of 3.0 m/s, tip
diameter of 3 mm and depth of 1 mm. Images from 24 hours and 6 weeks following
moderate injury show cortical tissue loss in the ipsilateral hemisphere (Figure 1.5. C-D),
in addition to the loss of Nissl-stained neurons (Figure 1.5. F) [42].
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Figure 1.4. Example of an Electromagnetic Controlled Cortical Impact System with
stereotaxic frame for stabilizing mice.

Figure 1.5. Brains collected from experimentation in the CCI model. a) 10-Week-Old
Mouse, b) Sham (Craniectomy Only), c) 24 Hr. Post Moderate TBI, d) 6 Weeks Post
Moderate TBI, e) Nissl Staining of Sham, f) Nissl Staining of Moderate TBI. This is
adapted from Romine, J., Gao, X., Chen, J. Controlled Cortical Impact Model for
Traumatic Brain Injury. J. Vis. Exp. (90), e51781, doi:10.3791/51781 (2014).
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1.4.2 Modified Controlled Cortical Impact
For the investigation into the biomechanics involved in mild TBI, in 2014,
Meaney et al. introduced a modified CCI model through adjustments to the mechanical
parameters discussed previously, in addition to the material and size of the impactor tip
[43]. This modified CCI model uses similar methodology and equipment as the
previously discussed CCI model, but with a much lower impact velocity of 0.43 m/s and
a larger impact depth of 2.1 mm [43]. The material and size of the impactor tip was
adjusted to produce a diffuse, mild injury. In this study, the impactor tip (4.0 mm
diameter) was manufactured from Sylgard-184 to produce a soft silicone tip capable of
producing a diffuse injury across a greater surface area of the brain [43]. Figure 1.6.
(Top) illustrates the comparison in tip size and region of injury between the mild CCI
(mCCI) impactor tip developed in this study and the traditional CCI impactor tip
comprised of metal, typically stainless steel [43]. Features of this model include
subcortical axonal injury, with no presence of visible lesions or hemorrhaging (Figure
1.6. Bottom) [43]. An additional point of consideration highlighted in this figure is the
lack of cortical lesion represented in both the sham and mCCI brain images. Several
reports have discussed the impact of craniectomies in elucidating changes in
inflammatory and behavior responses. Therefore, the incorporation of a sham model is
crucial in separating the effects from injury and surgical perturbation of the skull. This
injury design further illustrates the variation established with the use of CCI methods.
While this method requires further standardization, the variation in impactor tip hardness
provides the possibility for additional studies with ranging injury outcomes.
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Figure 1.6. Modified controlled cortical impact model. Top (B): Comparison between the
impactor tip size and region of injury between mild and traditional CCI (64). Bottom (D–
F): Brains 8 days post injury showing comparisons between sham, mild (mCCI) and
traditional CCI (tCCI). Reproduced with permission from [43].
1.4.3 Marmarou Weight Drop Model
The Marmarou weight drop model has a distinct experimental design that mimics
diffuse axonal injury experienced in clinical TBI, through impacting a greater surface
area of the skull and diffusing the primary injury throughout the brain [44, 45]. Following
a midline incision into the animal’s scalp, a stainless-steel disc is attached to the skull
with an adhesive glue between the lambda and bregma [44, 45]. This disc prevents skull
fractures upon impact from the free-falling weight, which is more frequent in the focal
injury weight drop models. Additionally, the animal is placed onto a foam bed to reduce
the deceleration of the animal’s head following impact (Figure 1.7.) [46].This reduction
in deceleration mitigates the risk of producing contrecoup injuries opposite the impact
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[19]. In a study conducted on rats in 1994, animals were impacted with a weight of 450
grams from heights of 1 or 2 meters [44]. Animals injured from 1 meter resulted in no
mortalities, while heights from 2 meters resulting in a 59% mortality rate [44]. However,
groups receiving intervention in the form mechanical ventilation did not result in
mortality for either height [44]. Both heights produced diffuse brain injuries with no
presence of focal lesions, while petechial hemorrhaging was associated with injuries
produced from the 2-meter height [44]. Neuronal injury was noticed in both ipsilateral
and contralateral cortices, in addition to DAI present in the corpus callosum, long tracts
in the brain stem, and to the cerebral and cerebellar peduncles [44]. Due to the
presentation of DAI following impact, Marmarou’s model has been well characterized in
literature, however it has been associated with a high mortality rate due to respiratory
depression without mechanical ventilation following injury.
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Figure 1.7. Illustration of a modified grade 1A Marmarou weight drop model. The
impact is delivered through a free-falling weight colliding with a helmet secured to the
animal’s head. The animal is placed onto a foam pad to decelerate impact and reduce the
risk of contrecoup injuries. Reproduced with permission from [46].
1.4.4 Modified Marmarou Weight Drop Model
While Marmarou’s weight drop model has shown to be successful in producing
features of diffuse injuries such as DAI, limitations in reproducibility have led
researchers to explore alternatives to the original methods established in 1994. The
diffuse injury model developed by Cernak, I et al. in 2004 incorporates a variety of
factors from the Marmarou Weight Drop Model and CCI model to develop a
reproducible diffuse moderate injury [47]. Following a midline incision through the scalp,
a steel disc (10 mm diameter, 3 mm thickness) is cemented to the animal’s skull using a
polyacrylamide adhesive [47]. The impactor tip uses the same steel disc as the one
attached to the animal’s head, so that there is no impact to the unprotected skull,
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minimizing the risk of fractures [47]. Lastly, the animal’s head is supported by a molded,
gel-filled base, similar to the foam base in Marmarou’s model [44, 47]. This base is used
to decelerate the animal’s head upon impact to prevent any injuries produced between the
animal and the hard surface below. The impact is produced by an air-driven high-velocity
impactor, similar to the pneumatic system used in CCI with a velocity of 3.25 m/s [4042]. Additionally, the depth of impact was 18-mm for this moderate TBI, with a mortality

rate of 26%. However, a range of depths from 16 mm to 20 mm was tested, with depths
of 19 and 20 mm representing severe TBI at 56 and 90% mortality rates, respectively.
This model showed increased edema and BBB permeability as early as 20 min following
moderate injury. Additionally, measurements in arterial blood pressure increased
immediately following injury and declined, reaching a minimum at 1 min post injury,
which was shown previously in Marmarou’s weight drop model [44]. Features of this
diffuse model include no focal lesions or contusions, with presence of subarachnoid and
intraventricular hemorrhages (Figure 1.8. C, black arrows) [47]. Overall, this model
provides unique advantages for producing DAI with enhanced reproducibility and
reduced mortality rate through the incorporation of an air-driven impactor capable of
making precise, automated adjustments to parameters such as speed and depth.
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Figure 1.8. Brain from a moderate diffuse injury model 24 hr following impact. a)
Superior surface, b) Inferior surface, c) Coronal view. Black arrows indicate presence of
subarachnoid and intraventricular hemorrhages. Reproduced with permission from [47].
1.5 Molecular Pathophysiology and Therapeutic Intervention in TBI
Several safety precautions have been implemented to prevent head trauma
including the provision and advancement of helmets, seatbelts, and airbags. However, the
major problem facing TBI patients is the spread of secondary corrosive damage to
surrounding brain tissue following primary impact. This lethal progression of secondary
damage is caused by a variety of biochemical malfunctions including blood brain barrier
(BBB) disruption, glutamate excitotoxicity, oxidative stress, and neuroinflammation
(Figure 1.9.) [21]. The BBB is a tightly regulated network of semi-permeable vasculature
designed to transport blood, ions, and molecules to the central nervous system, while
preventing the import of harmful toxins and pathogens [48, 49]. Impact forces associated

23

with TBI generate excess mechanical stress, which compromises the structural integrity
of the brain, resulting in a disruption of this vascularized system [49]. BBB breakdown
results in hemorrhaging from damaged blood vessels and impedes the flow of blood and
oxygen throughout the brain, corresponding to ischemia and hypoxia, respectively [6, 50].
Insufficient blood and oxygen intake halts neuronal ATP production, inhibiting the ATPdependent Na+/K+ pump, required to maintain a sufficient electrochemical gradient [5153]. These events lead to rapid neuronal depolarization lending to a corresponding influx

of calcium ions [51]. Under physiological conditions, calcium influx triggers the synaptic
release of a variety of neurotransmitters including glutamate [54]. Glutamate is an
excitatory neurotransmitter necessary for adequate brain functioning and plays a primary
role in learning and memory [54, 55]. Following TBI, excess influx of calcium into the
neuron leads to an upregulated release of glutamate which overstimulates glutamate
receptors, specifically NMDA, AMPA, and kainite receptors [56, 57]. Increased receptor
activation contributes to an excess influx of calcium into the cell which increases
mitochondrial dysfunction, drives the production of reactive oxygen species (ROS), and
can eventually lead to apoptotic cell death [33, 56, 57]. Upregulated cellular ROS induces
oxidative stress which forces a biochemical imbalance in the oxidant/antioxidant
equilibrium of the brain [21]. Oxidative stress leads to the damage of lipids, proteins, and
DNA in the brain and results in deterioration similar to the development of some
neurodegenerative diseases [21, 58]. Cellular damage facilitates neuroinflammation,
where neutrophils, lymphocytes, inflammatory cytokines, and microglia are recruited to
the site of injury to alleviate further damage [59, 60]. However, this pro-inflammatory
response persists and perpetuates an oversaturation of cytokines, specifically tumor
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necrosis factor alpha (TNF-α), leading to cell death [59-61]. Overall, these
pathophysiological consequences are primary factors influencing a cyclical cascade of
damage inducing cell dysfunction, cell death, and eventually the neuropathological
changes and behavioral deficits observed clinically. While these sequalae differ in their
mechanisms of biological dysfunction, their molecular consequences play a primary role
in the fate of the cell. Researchers have identified several forms and derivatives of cell
death, including apoptosis, ferroptosis, oncosis, and necroptosis [62-65]. Each of these
cellular processes is classified based on whether their induction is regulated or not.
Recommendations from the Nomenclature Committee on Cell Death 2018 conclude that
regulated cell death must be induced through an activation in signaling molecules[62].
These regulated mechanisms can be exploited, either through genetic or pharmacological
intervention[62]. Thus, understanding how the progression of cell death differs following
TBI provides valuable insight into potential therapeutic strategies.
Blood Brain
Barrier
Disruption

Glutamate
Excitotoxicity

Secondary
Injury

Inf lammation

Mitochond rial
Dysfunction

Figure 1.9. Secondary Consequences of TBI. Following TBI, the progression of
secondary injury leads to a variety of pathophysiological consequences including blood
brain barrier disruption, glutamate excitotoxicity, mitochondrial dysfunction, and
inflammation. Figure adapted from [21].
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1.5.1 Apoptosis, Necrosis, and Oncosis
Apoptosis is a form of caspase-mediated cell death induced by disruptions in the
microenvironment, including oxidative stress and DNA damage[62, 63, 66].
Mechanistically, apoptosis is subdivided into two pathways: intrinsic or extrinsic (Figure
1.10.)[62, 67]. Intrinsic apoptosis results in the formation of pores along the surface of the
outer membrane of the mitochondria, referred to as mitochondrial membrane
permeabilization (MMP)[62, 68]. MMP is regulated by apoptotic proteins in the BCL2
family, including BCL2 and BAX, which establish roles as anti-apoptotic and proapoptotic proteins, respectively[63]. MMP results in the release of cytochrome c from the
mitochondria. Cytochrome c binds and activates apoptotic protease activating factor 1
(APAF-1) resulting in the downstream activation of pro-caspase-9[62, 63, 69]. Procaspase 9 activation ultimately leads to the activation and cleavage of caspase-3 inducing
the progression of apoptosis[62, 63].
In contrast, extrinsic apoptosis is regulated through receptors located on the
surface of the plasma membrane[70]. This pathway relies on two distinct types of
receptors including death receptors and dependence receptors[62, 70, 71]. Death receptors
are dependent on ligand binding for activation, where in contrast, dependence receptors
are activated when the amount of binding substrate falls below a physiological
threshold[62]. Fas and tumor necrosis factor receptor 1 (TNFR1) are two types of death
receptors, whose substrates include Fas ligand (FasL) and TNF-α, respectively[62, 67, 70,
72]. Upon ligand binding, death-inducing signaling complex (DISC) is assembled at the

intracellular tail of the receptor leading to the downstream activation of pro-caspase-8[62,
73]. Pro-caspase 8 is cleaved upon activation leading to the activation and cleavage of
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caspase-3, as discussed in intrinsic apoptosis[63]. Cells undergoing both intrinsic and
extrinsic apoptosis maintain plasma membrane structural integrity and limited, but
sufficient, metabolic activity[62]. Thus, apoptosis is dependent on adequate levels of ATP
throughout the progression of cell death. This maintenance phase during apoptosis allows
for rapid clearance of damaged cellular components through macrophages, reducing the
likelihood of an inflammatory response[62, 74].

Figure 1.10. Mechanistic differences between intrinsic and extrinsic apoptosis. Apoptosis
is subdivided into two pathways: intrinsic and extrinsic. Intrinsic apoptosis is initiated
from mitochondrial stress leading to the release of cytochrome c and the downstream
activation of pro-caspase-9. In contrast, extrinsic apoptosis is induced through from
activation of death receptors located on the plasma membrane. Receptor activation leads
to activation of pro-caspase-8. Ultimately, both mechanistic pathways lead to the
activation and cleavage of pro-caspase-3 resulting in apoptosis. Reproduced with
permission from [67].
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Necrosis is a term used to describe the death of cells, or tissue, due to the extreme
physiological conditions caused by disease or injury [75, 76]. Previously, necrosis was
associated with the spontaneous, uncontrolled, pathological reaction of cell death, used to
contrast the mechanisms of apoptosis [64, 75]. However, following the induction of
damage, the cell undergoes three distinct phases including activation through signaling
transduction (pre-lethal), destruction associated with cell death (breaking point), and cell
lysis and degradation (post-mortem) [64]. Therefore, the term necrosis is more accurately
used to describe the end stage changes associated with cell death, rather than the cellular
and mechanistic changes inducing cell death. The cellular pathology opposite of
apoptosis is oncosis [64].
Oncosis is a cellular pathology caused by extreme pathophysiological
consequences including ischemia and hypoxia [64]. Both ischemia and hypoxia are
highly relevant in the context of TBI, specifically severe, focal TBI [77, 78]. Oncosis is a
regulated form of cell death induced through genetic, enzymatic, and environmental
factors, similar to apoptosis [62, 63, 79]. For example, recent evidence suggests that
oncosis can be triggered through increased mitochondrial permeability, resulting in a
dramatic decrease in mitochondrial membrane potential and reduction in intracellular
levels of ATP [62, 79]. However, oncosis differs primarily in three distinct aspects of cell
death including ATP dependence, cellular pathology, and inflammatory response.
Oncosis is initiated when external stimuli induce a disruption in the mechanisms involved
in ATP synthesis, resulting in decreased levels of ATP and an increase in intracellular
Na+ and Cl- [79, 80]. These increased intracellular ions lead to increased fluid uptake
inside the cell [62, 64, 79, 80]. Extracellular fluid builds up in the cell resulting in cell
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swelling, which is where the term “oncosis” originates, from the Latin translation for
swelling [64]. Cellular swelling continues leading to a complete physical breakdown of
the plasma membrane causing the release of damage-associated molecular patterns
(DAMPs) and other inflammatory cytokines [79, 81]. Ultimately, this inflammatory
response is a primary distinctions between the mechanisms of apoptosis and oncosis and
is actively being investigated in the context of TBI severity and mechanism [77].
1.5.2 Role of Apoptosis and Oncosis in TBI
Due to the relationship between secondary injury and cell death, apoptosis and
oncosis have been researched extensively in both clinical and pre-clinical TBI [77, 82-85].
Moderate to severe focal models, including CCI and fluid percussion injury, result in an
acute development of oncotic cell death, accompanied by apoptosis [82-84]. Closed head
mild TBI, including blast injuries, are typically absent of oncosis, but have been
associated with apoptotic cell death in both the acute and subacute period following TBI
[82, 85]. These observations have also been seen in clinical TBI studies [77]. Recent
reports have shown levels of caspase-3 in cerebrospinal fluid are correlated with TBI
severity [86]. Indeed, when coupled with intracranial pressure monitoring, apoptosis was
found to be significantly correlated with GCS scores and may play a role as a biomarker
for TBI prognosis [86]. Biomarkers of necrosis have also been correlated with clinical
TBI severity, including, α-II spectrin breakdown products (SBDP’s) [77]. A-II spectrin is
a molecular scaffold protein which is cleaved by both apoptotic, caspase-dependent, and
oncotic, calpain-dependent, pathways [77, 87]. Researchers identified a significant
correlation between oncotic SBDP’s, and GCS scores classified in the upper portion of
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the severe category (3-5) [77]. Thus, investigating these mechanisms of cell death is
critical for assessing potential therapeutic strategies of TBI.
1.5.3 Autophagy
While the mechanisms of apoptosis and necrosis differ, the stress response
experienced by the cell will end in the same result: cell death. However, cells also
possess specific machinery for overcoming these methods of cellular termination. In
these scenarios, the stress response is assessed, and rather than complete destruction, the
cell combats the stressor and adapts. This adaptive process experienced by the cell is
known as autophagy, translated from Greek meaning “self-eating” [88]. Autophagy is the
major metabolic pathway involving the assembly of aggregated proteins, and damaged
organelles, into autophagosomes to be degraded by lysosomes and further recycled for
the cell’s usage [89]. This evolutionarily conserved biological process is key for repairing
the body during periods of nutrient deprivation or during periods of stress [90, 91].
The mechanisms involved in the activation and continuation of autophagy are
vastly complex, containing multiple feedback loops, activation/inhibitory checkpoints,
and are still an active area of research and discovery. However, the generalized
mechanism is rather straightforward. During periods of cellular stress or nutrient
deprivation, metabolic processes involved in cell proliferation are stopped; namely lipid,
protein and nucleotide synthesis, to conserve energy and available resources [89, 92, 93]
(Figure 1.11.). This process begins with two primary upstream regulatory processes,
including the inhibition of the master regulatory protein complex, mechanistic target of
rapamycin (mTOR), as well as activation of AMP-activated protein kinase (AMPK) [92,
93]. Inhibiting mTOR allows for the translocation of transcription factor EB (TFEB) into
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the nucleus, which acts as the master regulator in lysosomal biogenesis and autophagy
[93, 94]. AMPK activates the unc-51 like autophagy activating kinase 1 (ULK1) complex,
leading to the phosphorylation of Beclin1, a core subunit of the PI3K complex, which
initiates the production of autophagosomes [92, 95, 96]. Autophagy related genes 3 & 7
(ATG3 and ATG7) are involved in the covalent linkage of phosphatidylethanolamine,
converting LC3-I into LC3-II [97-99]. LC3-II, or Microtubule-associated protein 1A/1B
light chain 3B, is involved in the formation of the autophagosome, specifically the
elongation of the phagophore [97, 98]. During this process, ubiquitin-binding protein P62
(also referred to as sequestome-1, SQSTM1), selectively binds to autophagic substrates
tagging them for autophagic accumulation [100]. The autophagosome continues to grow,
and expands around the tagged targets, until advancing into a mature autophagosome.
The final steps in autophagy involve autophagosomes fusing with lysosomes leading to
degradation, where nutrients can be recycled for the specific needs of the cell [89].
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Figure 1.11. Brief overview into the mechanisms of autophagy. Autophagy is induced
through cellular stress leading to the activation of AMPK. Downstream signaling leads to
the activation of Beclin1 initiating phagophore formation. ATG3 and ATG7 convert
LC3-I into LC3-II involved in the elongation of the phagophore. P62, selectively binds to
autophagic substrates tagging them for autophagic accumulation. Following maturation,
autophagosomes fuse with lysosomes to degrade these substrates where nutrients can be
recycled for the specific needs of the cell.
1.5.4 Role of Autophagy in TBI
Due to the implications for autophagy as a potential therapeutic target, there has
been a recent push to understand how autophagy is influenced following TBI [101, 102].
Autophagy activation was first reported following injury from a weight drop TBI model
[101]. Western blot analysis concluded that Beclin1 was significantly upregulated in the
ipsilateral hemisphere in the acute phase and remained elevated for three weeks following
injury [103]. Beclin1 was localized with both neurons and astrocytes, confirmed with
double immunofluorescence staining for NeuN and GFAP, respectively[103].
Additionally, autophagy activation has been reported clinically in children following
severe TBI [104]. ELISA analysis confirmed a significant upregulation of both Beclin1
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and P62 in cerebrospinal fluid [104]. These studies provide primary rationale for
investigating the mechanisms of autophagy following TBI. However, there is still debate
as to whether this biological process provides a positive or negative role following injury.
Rationale in support of autophagy as a protective role in TBI, originates from the
mechanistic understanding of the cross talk between apoptosis and autophagy [105, 106].
Both autophagy and apoptosis are induced by external stressors to the cell [63, 89].
However, both biological processes have shown to exhibit a mutual inhibition on one
another [107, 108]. Evidence has shown that upregulation of BCL-2 proteins inhibits the
mechanisms involved in Beclin1 autophagy activation [107]. Additionally, autophagy is
upregulated under physiological stress during nutrient deprivation and exercise, inhibiting
apoptosis and increasing the likelihood of cell survival [109]. Thus, autophagy activation
following TBI suggests a competitive inhibition of apoptosis to reduce cell death
following injury. Additional support for the protective role of autophagy in TBI is based
on evidence with the pharmaceutical, rapamycin [110] Rapamycin activates autophagy
through inhibition of the mTOR signaling pathway and was shown to improve
neurological severity scores as early as 48 hours following TBI, suggesting increased
neurobehavioral functioning [110, 111].
In contrast, several studies have reported that autophagy plays a negative role
following TBI [112, 113]. Treatment with the antioxidant, γ-Glutamyl cysteinyl ethyl
ester, was shown to reduce levels of LC3BII following controlled cortical impact and
improved performance in the Morris-water maze [112]. These results suggest that
antioxidant administration following TBI inhibits the activation of autophagy leading to
improved outcomes in behavioral assessments. Additionally, previous studies have
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shown that the autophagy inhibitors, 3-methyladenine (3-MA) and bafilomycin (BFA)
provide a therapeutic effect following impact [113]. Data concluded that these autophagy
inhibitors improved scores in behavioral outcomes and reduced lesion volume [113].
However, recent literature suggests a unique explanation for the changes in
autophagy following TBI, potentially providing rationale for the discrepancy between
previous studies [114, 115]. Following controlled cortical impact, researchers identified a
decrease in the activity of cathepsin D (CTSD), a lysosomal aspartyl protease, in the
lysosomal fraction of tissue lysates, and a corresponding increase in CTSD levels in the
cytosolic fraction [115]. Additionally, they observed a decrease in the colocalization of
LC3BII puncta with CTSD, when compared to sham [115]. These results, coupled with
significant increases in both LC3BII and SQSTM1, suggest autophagy may be
dysfunctional, leading to an accumulation in autophagic substrates caused by lysosomal
dysfunction [114, 115]. Indeed, further studies have shown that cytosolic phospholipase
A2 Group IVA (PLA2G4A), involved in the hydrolysis of phospholipid membranes, is
activated following TBI leading to a breakdown of the lysosomal membrane [114].
Additionally, these studies show that PLA2G4A inhibition attenuates autophagic
dysfunction and improves behavioral outcomes [114]. Therefore, autophagy may be
activated following TBI, but impaired due to lysosomal damage via lysosomal membrane
permeabilization (LMP) (Figure 1.14) [116]. LMP is induced through a variety of
mechanisms, including increased ROS production, resulting in the release of cathepsins
and other hydrolases from inside the lysosome [116-118]. Ultimately, LMP inhibits
lysosomal degradation and disrupting the mechanisms of autophagy [114-116]. Thus,
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developing therapeutic strategies for mitigating the production of ROS, may mitigate
LMP and lead to the physiological activation and continuation of autophagy.

Figure 1.12. Lysosomal Membrane Permeabilization (LMP) is induced through the
formation of pores in the lysosomal membrane leading the release of cathepsins and other
hydrolases involved in lysosomal degradation. LMP contributes to multiple pathways
involved in cell death including necrosis, apoptosis, and lysosome-dependent cell death.
Reproduced with permission from [116].
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CHAPTER 2: CHARACTERIZATION AND OPTIMIZATION OF A
CLOSED HEAD INJURY MODEL FOR ASSESSING VARIABILITY IN
TRAUMATIC BRAIN INJURY
2.0 Abstract
Animal models have been used extensively in neurotrauma research to simulate
injuries observed amongst the patient population. Due to the prevalence of mild traumatic
brain injury (TBI) clinically, researchers have emphasized the use of models which
produce diffuse, mild impacts. However, there are still no clinically approved
therapeutics for treating the secondary consequences associated with these injuries. Thus,
developing animal models which can produce mild TBI with automated, reproducible,
precision is imperative for understanding the pathophysiological consequences associated
with mild injuries. Here, we optimized and characterized a closed-head, mild injury
model using an electromagnetic controlled cortical impact (CCI) device. In our
preliminary evaluation, we determined that the actual impact speed produced from our
modified device was inconsistent with the input velocity parameter for our impact
system. Indeed, both input depth and velocity, influenced our actual impact speed, and
we found our maximum impact speed to be with an input velocity of 3.59 m/s and input
depth of 7.08 mm. Therefore, researchers should be cautious when using electromagnetic
CCI devices for replicating closed head mild TBI, to ensure results are interpreted based
on the appropriate impact parameters. Additionally, following impact, we examined
autophagic flux acutely following impact. Previous literature has shown that autophagic
flux is impaired acutely following severe impacts to the central nervous system.
Following DTBI, we observed autophagic dysfunction in the hippocampus at 1 day post
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impact in each of the three DTBI conditions. Overall, these results suggest that even
mild, diffuse TBI results in impaired cell turnover, thus may provide a therapeutic target
in a range of injury severities.
Key Words: Mild TBI, Controlled Cortical Impact, Marmarou Weight Drop
2.1 Introduction
Animal models have been used extensively in traumatic brain injury (TBI)
research to simulate clinical injuries and examine how primary impact influences the
progression of secondary damage [1, 19, 20, 38]. Most TBI models contain scalable
impact parameters, such as impact height, weight, velocity, and depth, capable of
producing a spectrum of injury severities, ranging from mild to severe TBI. Due to the
adjustable nature of these parameters, researchers have optimized impact models for
producing the relevant pathophysiological changes observed clinically. However,
secondary consequences following TBI are also influenced by the mechanism of injury
including focal impacts, diffuse impacts, and even non-impact TBI [3, 38]. Diffuse
impacts result from rapid acceleration and deceleration of the head driving compressive,
tensile and shear forces throughout the brain [33, 119]. This array of independent
directional forces is primarily due to the heterogeneous nature of tissue fixation and
tissue consistency in the brain [33]. For example, following a road traffic collision, the
brain continues accelerating in the direction of the applied force, where it meets against
the inner wall of the skull. However, diffuse injuries are observed in many other
situations, and are especially common amongst sports-related concussions. Currently, no
therapeutic interventions have been successful in treating the secondary damage
associated with diffuse impacts, owing to the current complications associated with injury
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heterogeneity and inadequate drug delivery [2, 14, 16]. Previously, the Marmarou weight
drop model was designed to simulate diffuse TBI for pre-clinical studies, and has been
characterized and used extensively throughout the field [44-46]. Due to the success of
Marmarou’s model, his methods have been modified and adapted to improve upon his
original experimental design. Indeed, several models have been developed with specific
emphasis on improving injury reproducibility and efficiency [47, 120]. Additionally,
current research has investigated these models for replicating pathophysiology associated
with repeated mild TBI [120-122]. Injury reproducibility is a primary criterion associated
with the controlled cortical impact (CCI) impactor device. CCI devices contain
modifiable impact parameters designed to generate precise, automated impacts. Thus, this
work aims to optimize and characterize a closed head injury model through modifications
to an electromagnetic controlled cortical impact device and evaluate the changes in
molecular pathophysiology associated with a range of impact parameters.
2.2 Materials and Methods
2.2.1 Antibodies
For Western Blot analysis, the following primary antibodies were used: β-Actin
(Mouse, Cat. #A2228, Sigma-Aldrich, 1:2,000) LC3B (Rabbit, Cat. #ab192890, Abcam,
1:1,000), and SQSTM1 (Mouse, Cat. #ab56416, Abcam, 1:500). β-Actin was used as a
loading control. Secondary antibodies for respective host species included Goat AntiRabbit (Cat. #1705046, Bio-Rad, 1:10,000) and Goat Anti-Mouse (Cat. #1705047, BioRad, 1:10,000).
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2.2.2 Modified Marmarou Weight Drop Model
All surgical procedures and experiments were performed in accordance with the
Animal Care and Use Committee at the University of Nebraska Lincoln. All injuries were
performed on 8-week old C57BL/6J mice (N=3) using an electromagnetic CCI device
(PCI3000, Hatteras Instruments). Prior to impact, mice were anesthetized under 3.0%
isoflurane in a plexiglass chamber, placed onto a bed platform and secured using a
stereotaxic frame (David Kopf Instruments, Model 963). Isoflurane was held at 1.5% for
the remainder of the procedure. Buprenorphine SR (0.5 mg/mL) was administered via
dorsal subcutaneous injection to the skin flap of the mouse. Hair was removed from the
scalp with Nair and a lidocaine/bupivacaine (20 mg/ml) solution was applied dropwise as
a local anesthetic. Iodine was applied to the scalp, followed by a 1 cm incision through
the midline to expose the skull. Following surgical preparation, a steel helmet comprised
of stainless-steel (10 mm diameter x 3 mm thickness) was secured to the midline of the
exposed skull using an adhesive glue. The impactor is also comprised of stainless steel
and is the same size as the helmet to ensure the skull is completely protected from
impact. For impact speed analysis without the use of animals, impacts were delivered
using the electromagnetic CCI device with input velocities of 2, 3, and 4 m/s and depths
at 3, 9 and 15 mm. For in vivo analysis, input velocity was fixed at 3.3 m/s with depths at
3, 9 and 15 mm. Impact dwell time remained constant at 80 ms. Additionally, the mouse
was placed onto a 1-in foam pad, with head placed onto a smaller foam pad (~15 mm), to
dissipate the acceleration from impact.
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2.2.3 Phantom Miro 310 Videography and Impact Speed Calculations
The Phantom Miro 310 high speed camera was used to record videos of impacts
from each experimental condition, without the use of animals, to be used for calculating
the actual impact speed. Video parameters are included here: (Resolution: 256x128;
Frame Rate: 2,000 fps; Exposure Time: 490 μs). Images were captured throughout the
impact including: the starting position, where the impactor was at the highest point prior
to impact, the ending position, where the impactor would contact the steel helmet, and 5
frames prior to reaching the end position. Positions at 5 frames prior to impact were used
as an arbitrary metric to compare relative impact velocities between each of the
experimental conditions. Impact heights were determined using a proportional
relationship between the size of the red sticker, placed on the impactor, and the pixel size
of the sticker (Equation 1). The actual impact speed was calculated by determining the
change in position between the impact height at 5 frames prior to impact to the end
position (Equation 2).
𝑫𝑫

𝑯𝑯

𝑯𝑯𝑰𝑰

Equation 1: 𝑫𝑫 𝑹𝑹 = 𝑯𝑯 𝑰𝑰

Equation 2:

DR: Diameter of Red Sticker (In.)

DPR: Diameter of Red Sticker (Px.)

HI: Height of Impactor (In.)

HPI: Height of Impactor (Px.)

X: # of Frames until End Position

FR: Frame Rate (FPS)

Variables:

𝑷𝑷𝑷𝑷

𝑷𝑷𝑷𝑷

𝑿𝑿

∗ 𝑭𝑭𝑭𝑭 = 𝑽𝑽

V: Final Impact Speed (m/s)
2.2.4 Regression Model of Impact Speed
Impact speeds for each experimental condition were used for generating a
regression model of impact speed using Statistical Analysis System (SAS). Briefly, SAS
was used to generate an analysis of variance table for determining which factors provided
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a significant effect on impact speed. Results were used to create an analysis of contrasts
table. Analysis of contrasts was used to determine how each factor influenced the impact
speed response, and whether those factors behaved linearly or quadratically. Significant
contrasts were used to determine which parameter coefficients would be incorporated in
our regression model. Relevant SAS Code used for our impact speed analysis is provided
(Appendix A.)
2.2.5 Tissue Lysate Preparation
For in vivo analysis, mice from each group (N=3) were perfused with PBS at a
fluid pressure of 80 mmHg. Perfusions were conducted at days 1, 3, and 7 post injury.
Following perfusions, brains were harvested and separated into four regions: left cortex
(LC), right cortex (RC), left hippocampus (IH) and contralateral hippocampus (CH) using
methods described previously [123]. Samples were homogenized using bead disruption
(TissueLyser II, Qiagen) in 300 μL of RIPA buffer (50 mM Tris HCl pH 8.0, 150 mM
NaCl, 1% Triton X-100, 0.5% Na Deoxycholate, 0.1% SDS, 1 mM EOTA, 0.5 mM
EGTA, 1 mM PMSF, 1 mM Na3VO4, 1 mM NaF). Brain samples were sonicated using a
horn sonicator for 20s at 20% pulse frequency and then centrifuged in 4 ºC for 5 minutes
at 17,740 rcf. Tissue supernatant was collected, and total protein content was measured
using a bicinchoninic acid (BCA) assay. Aliquoted tissue lysates were loaded with BMercaptoethanol and 4x Laemlli Buffer (1:9 ratio), boiled at 95 °C for 5 minutes and
stored at -20 °C.
2.2.6 Western Blot Analysis
Western blot analysis was used for assessing changes in protein biomarkers.
Casted polyacrylamide gels (13%) were loaded with tissue lysates at 30 μg of total
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protein content. Proteins were separated through gel electrophoresis at 120 V for
approximately 60 minutes. Proteins were transferred onto PVDF membranes, using a wet
transfer tank, overnight at 25 V. Membranes were washed with TBS (2 x 5 minutes) and
incubated for 1 hour at room temperature in blocking buffer (5% Blot-Quick Blocker
Reagent in TBST). Membranes were then incubated overnight in primary antibody
solution and washed with TBST (3 x 5 minutes). After washing, membranes were
incubated with secondary antibody for 1 hour and washed with TBST (3 x 10 minutes).
ECL was then added dropwise and left to set for approximately 5 minutes prior to
imaging. Imaged bands were quantified using the adjusted volume quantity from drawn
regions of interest.
2.2.7 Statistical Analysis
All data are represented as mean ± standard deviation (SD) with N=3 for all
groups. Statistical analysis was performed using GraphPad Prism (version 9.3.1) and all
graphs were generated using this software. Prior to running comparative analysis, all data
was first analyzed for normality using the Shapiro-Wilk Test, and all data collected
passed this test. For examining comparisons of injury timeline to control, data was
analyzed using Two-way ANOVA with Dunnett’s multiple comparisons test for post hoc
analysis (#: CTRL vs DTBI). For examining comparisons between injuries, data was
analyzed using Two-Way ANOVA with Tukey’s Honest Significantly Difference test for
post hoc analysis (*: Differences between DTBI groups)
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2.3 Results
2.3.1 Inconsistency between input parameters and output conditions
Impact parameters from our electromagnetic impact system, including depth and
velocity, were adjusted to determine an optimal impact speed for reproducing diffuse,
mild TBI. Upon preliminary investigation, we observed that the starting impact height for
each condition was dependent on the parameter depth. These preliminary observations
suggested that the actual impact speed from our modified Marmarou weight drop model
was inconsistent with the parameter velocity. To assess these inconsistent results, we
used a high-speed camera (Phantom Miro M310) to record videos from an experimental
matrix of DTBI conditions, without the use of animals. Images were captured throughout
the duration of impact and used to calculate the actual impact speed. Parameters for this
experiment included input velocities at 2, 3, and 4 m/s with depths at 3, 9 and 15 mm.
Videos were recorded, and captured images were used to determine how starting impact
height and impact velocity differed for each of the 9 experimental conditions (Figure
2.1.). We observed that the actual impact speed was the greatest at an impact depth of 9
mm for each of the three input velocities (Figure 2.2.). In addition, the actual impact
speed was lowest at an impact depth of 15 mm for each respective velocity, which did not
coincide with our original hypothesis. Interestingly, we observed that the difference
between impact speeds for 3 and 9 mm depths decreased as we increased our input
velocity, such that actual speeds for these depths were the most similar at 4 m/s (Figure
2.3.). These results coincided with our previous findings, which suggested that both input
depth and velocity influenced our actual impact speed. Additionally, impact speeds were
fairly constant at 15 mm depths, regardless of input velocity. Overall, these results
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suggest that both velocity and depth are important factors for influencing our impact
speed response.

15 mm

9 mm

3 mm
2 m/s
3 m/s
4 m/s

Figure 2.1. Images captured during impact for each experimental DTBI condition.
Impact position was located at 5 frames prior to contact with the green tape for each
experimental condition. Impact position was different for each DTBI impact, suggesting
final impact speeds were different between groups.

2 m/s
3
2
1
0

✱✱

✱✱

3 m/s
✱

✱✱

4 m/s
✱

✱

3 mm
9 mm
15 mm

Figure 2.2. Calculated impact speeds for each experimental condition of the DTBI
matrix. Impact speeds were the greatest at a depth of 9 mm, and lowest at 15 mm
regardless of input velocity. Additionally, the difference between impact speeds for 3 and
9 mm depths decreased as we increased input velocity.
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Speed vs Velocity

2.5

3 mm
9 mm
15 mm

2.0
1.5
1.0

2 3 4
Veloci ty (m/s)

Figure 2.3. Calculated impact speed with respect to input velocity. We observed that the
difference between impact speeds at 3 and 9 mm depths decreased as we increased our
input velocity. Additionally, actual impact speeds were fairly constant at 15 mm depths.
Overall, these results suggest a combinatorial effect from both input depth and velocity.
2.3.2 Impact speed highly influenced by impact depth
Our previous results for calculated impact speed suggested there was interaction
between depth and velocity indicating each factor is dependent on the other, providing a
combinatorial effect. Results from our analysis of variance (ANOVA) table conclude that
the actual impact speed was significantly affected by both factors (depth and velocity), as
well as the interaction effect between the two factors determined by the p-values
highlighted inside the blue box (Table 2.1.). Due to the nature of our experimental
conditions; equally spaced, quantitative factors (Velocity: 2.0, 3.0, 4.0 m/s and Depth: 3,
9 and 15 mm), we used analysis of contrasts to determine how each factor influences our
actual impact speed response. Results from our analysis of contrasts table conclude that
our impact speed response curve increases both linearly and quadratically with respect to
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both factors, based on the p-values highlighted inside the blue box (Table 2.2.).
Additionally, we identified a linear interaction between each factor, which suggests that
actual impact speed increased linearly with respect to linear changes in depth. However,
this information does not provide a complete picture for the accurate interpretation of our
impact speed response curve. Therefore, using SAS, we identified the relevant parameter
coefficients for fitting our regression model. Table 2.3. provides a list of coefficients used
for fitting the appropriate regression model shown below in Equation 7. Ultimately, this
regression model was used for accurately describing the effect of both factors on actual
impact speed, and the parameters needed for achieving a maximum impact speed can be
derived using multivariate implicit differentiation (Appendix B.) Previous impact
calculations, along with the derived maximum impact speed of 2.32 m/s, were compared
against actual impact speeds from our equation (Table 2.4.). However, the maximum
impact speed can also be found using the response curve plot created from our fitted
regression model (Figure 2.4.).
Table 2.1. Analysis of variance (ANOVA) table used to determine the significance of
input factors. We determined that depth, velocity, and their interaction were each
significant regarding their influence on impact speed response. Abbreviations: d (Depth),
v(Velocity) d*v (Depth*Velocity interaction).
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Table 2.2. Analysis of contrasts table used to determine the shape of the response curve
regarding actual impact speed. Impact speed behaved linearlly and quadratically with
respect to both factors. Additionally, there was a linear interaction between both factors
suggesting that impact speed increased linearly with respect to linear changes in depth.

Table 2.3. Coefficients for factors found to be significant from analysis of contrasts table.
These coefficients were used for generating our fitted regression model shown below.

Equation 7: Fitted regression model of impact speed response curve.
𝒀𝒀 = −𝟏𝟏. 𝟏𝟏𝟏𝟏𝟏𝟏 + 𝟎𝟎. 𝟐𝟐𝟐𝟐𝟐𝟐 + 𝟏𝟏. 𝟒𝟒𝟒𝟒𝟒𝟒 − 𝟎𝟎. 𝟎𝟎𝟎𝟎𝟎𝟎𝒅𝒅𝟐𝟐 − 𝟎𝟎. 𝟏𝟏𝟏𝟏𝟏𝟏𝒗𝒗𝟐𝟐 − 𝟎𝟎. 𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎
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Table 2.4. Data table for comparing calculated impact speeds with actual impact speeds
generated from fitted regression model. Input parameters for achieving a maximum
impact speed are highlighted below in blue.
Depth

Input

Calculated Impact

Actual Impact

(mm)

Velocity (m/s)

Speed (m/s)

Speed (m/s)

3

2

1.48

1.52

9

2

1.93

1.94

15

2

1.56

1.56

3

3

2.04

2.00

9

3

2.27

2.25

15

3

1.61

1.70

3

4

2.14

2.15

9

4

2.18

2.23

15

4

1.53

1.51

7.08

3.59

N/A

2.32
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Figure 2.4. Surface response curve generated from our fitted regression model.
2.3.3 Effect of input parameters on molecular pathophysiology
Based on our previous analyses, we determined that the maximum impact speed
was 2.32 m/s, with an input velocity and depth at 3.59 m/s and 7.08 mm, respectively.
However, we were primarily interested in understanding how biomarkers changed over a
range of impact depths. Indeed, for an impact depth of 9 mm, an input velocity of 3.3 m/s
would achieve the highest actual impact speed at 2.28 m/s, comparable to our maximum
impact speed (Table 2.5.). Thus, for in vivo impacts, we chose to examine each depth (3,
9, 15 mm) at an impact speed of 3.3 m/s (Figure 2.5.). For identifying changes in
pathophysiology, we chose to investigate biomarkers associated with cell turnover,
specifically autophagy. Autophagy is a metabolic pathway involved in the aggregation
and degradation of damaged or dysfunctional organelles [89]. Previous literature has
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demonstrated that following TBI autophagy is dysfunctional, suggesting impaired
autophagic flux [114, 115]. Autophagic flux refers to the activity of autophagic
degradation completed by lysosomes. Both autophagosomes and their substrates are
degraded by lysosomes following a complete cycle of cellular turnover. Thus,
corresponding increases in LC3BII, representing autophagosomes, and SQSTM1,
representing autophagic substrates, suggest autophagic flux is disrupted leading to an
accumulation of cellular components inside the lysosome. Impaired autophagic flux has
been reported previously following severe injuries to the central nervous system and
plays an active role in a variety of neurodegenerative processes [114, 115, 124, 125]. Thus,
we sought to determine if autophagic flux was impaired following mild, diffuse TBI.
Following injuries from each respective impact depth, we observed impaired autophagic
flux in the hippocampus (HC) at 1 day post impact (Figures 2.6., 2.7., 2.8.). However,
autophagy recovered at days 3 and 7, suggesting that diffuse, mild injuries result only in
acute autophagic dysfunction. Additionally, we observed a peak in LC3BII only in the
cortex at 3 days post injury following both the 3 mm and 15 mm impact depths.
Interestingly, following the 9 mm impact depth, we observed a peak in SQSTM1 at 3
days post injury in the cortex, with no corresponding increase in LC3BII. Overall, these
results suggest that diffuse mild impacts result in acute autophagic dysfunction in the
hippocampus. However, there may be an impact threshold for observing autophagic
dysfunction in the cortex, as we did see increases in SQSTM1 in the cortex, produced
from the highest impact speed.
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Table 2.5. Data table of calculated impact speeds used in our in vivo experiment. For an
input velocity of 3.3 m/s, at an impact depth of 9 mm, we achieved our peak impact speed
at 2.28 m/s.
Depth (mm)
3
9
15

Input Velocity (m/s)
3.3
3.3
3.3

Actual Impact Speed
(m/s)
2.08
2.28
1.68

3.3 m/s

3 mm

9 mm

15 mm
Figure 2.5. Images captured at the starting impact position for each of the three
experimental DTBI conditions with an impact velocity of 3.3 m/s. Starting impact
positions were different for each of the three conditions, coinciding with our previous
findings.
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CTRL

LC

RC

LH

RH

SQSTM1
LC3BI
LC3BII
β-Actin
SQSTM1
LC3BI
LC3BII
β-Actin

CTRL

CTRL

CTRL

Day 7
Day 1
Day 3
3 mm
D1
D3
D7

D1

D1

D3

D3

D7

D7

SQSTM1
LC3BI
LC3BII
β-Actin
SQSTM1
LC3BI
LC3BII
β-Actin

CTRL

D1

D3

D7

5
4
3
2
1
0

3 mm Cortex

✱✱

LC3BII

SQSTM1

3 mm HC
5 ✱✱✱✱
✱✱
4
✱
✱✱
3
2
1
0
LC3BII SQSTM1

Figure 2.6. Western blot images and quantified data for autophagy biomarkers at 1, 3 and
7 days post DTBI at 3 mm impact depth. LC3BII peaked at 3 days post impact in the
cortex, with no corresponding increase in SQSTM1. However, impaired autophagic flux
was observed in the hippocampus at 1 day post impact.
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RC
LH

RH

SQSTM1
LC3BI
LC3BII
β-Actin
SQSTM1
LC3BI
LC3BII
β-Actin
SQSTM1
LC3BI
LC3BII
β-Actin
SQSTM1
LC3BI
LC3BII
β-Actin

CTRL

CTRL

Day 3
9 mm
D1
D3

D1

CTRL

D1

CTRL

D1

D3

D3

D3

Day 7
D7

D7

Ratio to CTRL

LC

Day 1

D7

D7

Ratio to CTRL

CTRL

5
4
3
2
1
0

9 mm Cortex
✱

LC3BII

SQSTM1

9 mm HC
5
✱✱
4
P=0.066
3
2
1
0
LC3BII
SQSTM1

Figure 2.7. Western blot images and quantified data for autophagy biomarkers at 1, 3 and
7 days post DTBI at 9 mm impact depth. SQSTM1 peaked at 3 days post impact in the
cortex, with no corresponding increase in LC3BII. However, impaired autophagic flux may
be present in the hippocampus at 1 day post impact.
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Day 1
Day 3
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LC3BI
LC3BII
β-Actin

D1

D3

5
4
3
2
1
0

D7

SQSTM1
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LC3BII
β-Actin
CTRL
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D7

✱✱✱
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LC3BII

SQSTM1
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4
3
2
1
0

✱

✱

LC3BII

✱
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Figure 2.8. Western blot images and quantified data for autophagy biomarkers at 1, 3 and
7 days post DTBI at 9 mm impact depth. LC3BII peaked at 3 days post impact in the cortex,
with no corresponding increase in SQSTM1. However, impaired autophagic flux was
observed in the hippocampus at 1 day post impact.
2.4 Discussion & Limitations
Recent efforts in the field of neurotrauma have prioritized developing mild TBI
models, due to the overwhelming abundance of mild injuries observed clinically. Current
challenges facing clinical trials and pre-clinical translation are primarily due to an
incomplete understanding of the pathophysiology associated with closed head, diffuse
injuries. Thus, investigating mild, diffuse impact models is imperative for overcoming
these current limitations. Through this work, we characterized and optimized a closed
head, mild injury model (DTBI) using an electromagnetic CCI device. These impact
devices are valuable for producing injuries, due to the precise, automated, reproducibility
associated with the impactor. However, our results suggest that these impacts may not be
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directly correlated with the set experimental parameters of our electromagnetic impact
system. Results from videographic analysis using the Phantom Miro 310 concluded that
actual impact speeds were highest with an impact depth of 9 mm, and we observed
similar impact speeds at 15 mm impact depth regardless of impact velocity. Additionally,
using our fitted regression model, we calculated a maximum impact speed of 2.32 m/s,
with an input impact velocity of 3.59 m/s and depth at 7.08 mm. This maximum impact
speed is far lower than the maximum input velocity of 4 m/s, ultimately leading to
reduced impact forces and cognitive deficits. Overall, these results suggest that the actual
impact speed for our DTBI model does not reflect the input parameter for impact velocity
and is highly influenced by the impact depth. Therefore, we believe that it is imperative
that researchers first characterize their closed head injury models when using the CCI
system to ensure that data is interpreted based on the actual injury outcome, and not the
input parameters. Additionally, we investigated how actual impact speed influenced the
mechanisms of cell turnover, specifically autophagy. Previous literature has shown that
autophagic flux is impaired following severe, focal CCI [114, 115]. However, these
injuries are not representative of the patient population, and the mechanisms of
autophagy may remain functional following closed head, mild impacts. Thus, we sought
to determine if autophagic flux was impaired following mild, diffuse TBI using a range
of impact depths, which corresponded with ranges in impact speed. Interestingly,
following DTBI at each respective impact depth of 3, 9 and 15 mm, we observed
impaired autophagic flux in the hippocampus (HC) at 1 day post impact. Autophagy
recovered at days 3 and 7, suggesting that diffuse, mild injuries result only in acute
autophagic dysfunction. However, this acute dysfunction resulted from a single impact,
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suggesting that impaired autophagic flux may be exacerbated following repeated mild
impacts. Additionally, we observed that autophagy remained functional in the cortex
following both the 3 mm and 15 mm impact depths. Interestingly, following the 9 mm
impact depth, we observed a peak in SQSTM1 at 3 days post injury in the cortex, with no
corresponding increase in LC3BII. While these results do not confirm autophagic
dysfunction in the cortex following DTBI, there may be an impact threshold for
observing autophagic dysfunction in the cortex, as we did see increases in SQSTM1 in
the cortex, produced from the highest actual impact speed. Overall, these results suggest
that autophagy is dysfunctional following a range of closed head, diffuse impacts. Thus,
impaired autophagic flux may play a role as a potential therapeutic target for treating the
secondary consequences associated with the spectrum of injury severities and
mechanisms observed clinically.
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CHAPTER 3: EFFECT OF INJURY SEVERITY AND MECHANISM ON
THE CROSSTALK BETWEEN THE MECHANISMS OF CELL DEATH
AND SURVIVAL
3.0 Abstract
Traumatic brain injury (TBI) mechanism and severity are heterogenous clinically,
resulting in a multitude of physical, cognitive, and behavioral deficits. However,
approximately 80% suffer from milder injuries. Thus, examining pathophysiological
changes associated with mild TBI is imperative for improving clinical translation and
evaluating the efficacy of potential therapeutic strategies. Here, we employed derivations
of the controlled cortical impact (CCI) model, including traditional, severe CCI (CCI, 4
m/s velocity, 2.5 mm depth), mild CCI with silicone tip (MTBI, 0.4 m/s velocity, 2 mm
depth), and closed skull CCI with protective helmet (DTBI, 3.3 m/s velocity, 9 mm
depth). Injuries were performed on 8-week old male C57BL/6J mice (N=3), and perfused
at 1, 3, and 7 days post-injury. Western blot results of α-II spectrin breakdown products
(SBDP’s) confirmed a peak in oncotic cell death at 3 days post CCI in all regions, and
both mild models were absent of oncosis. However, SBDP’s for total cell death and
apoptosis did differ between mild models, suggesting that impact mechanism alone is
enough to influence molecular pathophysiology. These differences in apoptosis were also
observed by measuring changes in the pro-apoptotic protein, BAX. Additionally, Western
blot results for autophagic markers, LC3BII and SQSTM1, indicated autophagic flux was
impaired in the LH following impacts from each TBI model. Preliminary results
confirmed autophagic dysfunction in the left cortex by evaluating LC3BII localization
through confocal microscopy at 3 days post injury, which corresponded with peaks in
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oncotic cell death. Thus, mechanisms of cell death and turnover are highly variable
depending on mechanism and severity of TBI, and autophagic dysfunction may play a
critical role in the progression of secondary injury following impact.
Key Words: Concussion/mTBI, Secondary Injury, Cell Death, Autophagy
3.1 Introduction
Traumatic brain injury (TBI) is currently the leading cause of injury related
morbidity and mortality worldwide, with an estimated global cost of $400 billion
annually [2]. Injury mechanism and severity present heterogeneously in the patient
population resulting in a multitude of physical, cognitive, and behavioral deficits. Based
on the Glasgow Coma Scale, an assessment used for classifying TBI clinically, injury
severity can be categorized into three distinct groups: mild, moderate, and severe [22, 23].
Epidemiological reports from the CDC conclude that mild TBI represents approximately
80% of the patient population, while moderate and severe injuries represent
approximately 10%, respectively [27]. Additionally, injury severity can be subcategorized based on the mechanism of impact including focal, diffuse, and non-impact
TBI [32, 36, 37]. Following impact, a progression of secondary damage results in a
cascade of pathophysiological events including blood brain barrier disruption, glutamate
excitotoxicity, and oxidative stress [21]. These injury sequalae evolve over time resulting
in corresponding changes in biomarkers, imaging characteristics, and behavioral
outcomes. Overall, this heterogeneity amongst the clinical population, with respect to
both injury and outcome, is one of the primary contributors to problems currently facing
clinical trials and preclinical translation [9, 11, 14, 15]. Indeed, this hallmark of variability
has critically impacted the lack of success experienced in phase III clinical trials for TBI,
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and yet, researchers are still faced with an incomplete understanding of pathophysiology
regarding injury heterogeneity [12]. Thus, there is a critical need to identify these changes
in molecular pathophysiology, to improve upon our understanding of how injury
variability influences the progression of secondary damage following TBI. Previous
research has employed the use of animal models designed to mimic the biochemical and
neuropathological changes experienced following TBI [1, 19, 20]. However, investigating
changes associated with individual models limits the scope of discovery regarding injury
heterogeneity. In addition, several previously developed models have the propensity to
produce moderate to severe, focal injuries, which are currently underrepresented in the
clinical population [39, 126, 127]. While these pre-clinical injuries are valuable for testing
the efficacy of theranostic tools, these interventions must be evaluated amongst of a
spectrum of injuries to ensure adequate targeting and efficacious drug delivery.
Additionally, these assessments could provide insight for understanding how molecular
pathophysiological mechanisms are influenced following injury. Previous studies in both
pre-clinical and clinical TBI have already identified several differences regarding
mechanisms of cell death and cell turnover in response to injury severity [77, 83, 104,
115]. Results from these studies indicate a shift in oncosis following severe TBI and these

changes may influence the functionality of autophagic turnover. Thus, this work aims to
determine how cell death and autophagic turnover are influenced based on TBI injury
severity and mechanism.

59

3.2 Materials and Methods
3.2.1 Antibodies
For Western Blot analysis, the following primary antibodies were used: β-Actin
(Mouse, Cat. #A2228, Sigma-Aldrich, 1:2,000), α-II Spectrin (Mouse, Cat. #MAB1622,
Sigma-Aldrich, 1:1,000), BAX (Rabbit, Cat. #2772, Cell Signal.), LC3B (Rabbit, Cat.
#ab192890, Abcam, 1:1,000), and SQSTM1 (Mouse, Cat. #ab56416, Abcam, 1:500). βActin was used as a loading control. Secondary antibodies for respective host species
included Goat Anti-Rabbit (Cat. #1705046, Bio-Rad, 1:10,000) and Goat Anti-Mouse
(Cat. # 1705047, Bio-Rad, 1:10,000). Immunostaining for confocal microscopy was done
with the following primary antibodies: LC3B (Rabbit, Cat. #ab192890, Abcam, 1:250)
and LAMP1 (Rat, Cat. #ab25245, Abcam, 1:250). Secondary antibodies for respective
host species included Donkey Anti-Rabbit (Cat. #ab150063, Abcam, 1:250) and Goat
Anti-Rat (Cat. #ab150158, Abcam, 1:250).
3.2.2 Controlled Cortical Impact Model
All surgical procedures and experiments were performed in accordance with the
Animal Care and Use Committee at the University of Nebraska Lincoln. All injuries were
performed on 8-week old C57BL/6J mice (N=3) using an electromagnetic controlled
cortical impact (CCI) device (PCI3000, Hatteras Instruments). Prior to impact, mice were
anesthetized under 3.0% isoflurane in a plexiglass chamber, placed onto a bed platform
and secured using a stereotaxic frame (David Kopf Instruments, Model 963). Isoflurane
was held at 1.5% for the remainder of the procedure. Buprenorphine SR (0.5 mg/mL) was
administered via dorsal subcutaneous injection to the skin flap of the mouse. Hair was
removed from the scalp with Nair and a lidocaine/bupivacaine (20 mg/ml) solution was
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applied dropwise as a local anesthetic. Iodine was applied to the scalp, followed by a 1
cm incision through the midline to expose the skull. Following surgical preparation,
craniectomy was performed using a 2.5 mm trephine drill tip to remove a cranial flap,
located at 2 mm posterior of bregma and 2 mm left of the midline. Following bone flap
removal, injury was induced using the CCI device with a stainless steel impactor (2.0 mm
diameter). Velocity, depth, and dwell time are input at 4 m/s, 2.5 mm depth, and 80 ms,
respectively.
3.2.3 Modified Mild TBI Models
Modified mild TBI models were established based on methodology from
previously developed protocols [43, 47]. In the MTBI model, the size of craniectomy was
increased to 5 mm and a silicone tip (4 mm diameter) was used for the impact, fabricated
from a SylgardTM 184 Silicone Elastomer Kit. Silicone elastomer solution was prepared
with a 10:1 ratio of silicone to catalyst, syringed directly inside a custom-made Teflon
mold before being placed inside an oven at 150 ºC for 1.5 Hours. The impact velocity
was lowered to 0.4 m/s, with a depth of 2 mm and dwell time of 80 ms. For the DTBI
model, the impactor tip was comprised of a stainless-steel disc (10 mm diameter x 3 mm
thickness). There was no craniectomy as the mouse’s skull was protected by a steel
helmet of the same size as the impactor and secured to the midline of the exposed skull
using an adhesive glue. Additionally, the mouse was placed onto a 1-in foam pad, with
head placed onto a smaller foam pad (~15 mm), to dissipate the acceleration from impact.
3.2.4 Tissue Lysate Preparation
Mice from each group (N=3) were perfused with PBS with a pressure of 80
mmHg at 1, 3, and 7 days post injury. Brains were then harvested and separated into four
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regions: left cortex (LC), right cortex (RC), left hippocampus (IH) and contralateral
hippocampus (CH) using methods described previously [123]. Samples were
homogenized using bead disruption with the TissueLyser II (Qiagen) in 300 μL of RIPA
buffer (50 mM Tris HCl pH 8.0, 150 mM NaCl, 1% Triton X-100, 0.5% Na
Deoxycholate, 0.1% SDS, 1 mM EOTA, 0.5 mM EGTA, 1 mM PMSF, 1 mM Na3VO4,
1 mM NaF). Samples were then sonicated using a horn sonicator for 20s at 20% pulse
frequency and centrifuged in 4 ºC for 5 minutes at 17,740 rcf. Supernatants were
collected and total protein content was measured using a bicinchoninic acid (BCA)
Assay. Aliquoted tissue lysates were then loaded with B-Mercaptoethanol and 4x Laemlli
Buffer (1:9 ratio), boiled at 95 °C for 5 minutes and stored at -20 °C.
3.2.5 Western Blot Analysis
For assessing SBDP’s, polyacrylamide gels were casted at a thickness of 1 mm
using two different percentages including: 1 mL of 12% on bottom, immediately
followed by approximately 4 mL at 5%. Tissue lysates were loaded with a total volume
of 5 μL in each well at a protein concentration of 1 μg/μl. For assessing all other markers,
polyacrylamide gels were casted with a gel percentage at 13% and tissue lysates were
loaded at 30 μg of total protein content. Proteins were separated through gel
electrophoresis at 120 V for approximately 80 minutes. For all casted gels, proteins were
transferred onto PVDF membranes, using a wet transfer tank overnight, at 25 V.
Membranes were washed twice with TBS for 5 minutes and incubated for 1 hour at room
temperature in blocking buffer (5% Blot-Quick Blocker Reagent in TBST). Membranes
were then incubated overnight in primary antibody solution and washed three times with
TBST for 5 min. Following washing, membranes were incubated with secondary
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antibody for 1 hour and washed three times with TBST for 10 minutes. ECL was then
added dropwise and left to set for approximately 5 minutes prior to imaging. Imaged
bands were quantified using the adjusted volume quantity from drawn regions of interest.
3.2.6 Cryosection Preparation
Mice from each group (N=3) were perfused with 4% PFA at 3 days post injury,
and brains were harvested and stored in 4% PFA for 24 hours. Fixed brains were rinsed
and then washed with PBS twice for 5 minutes. After washing, brains were submerged in
30% sucrose and left to sink for 72 hours. Brains were then sliced through the coronal
plane at approximately 2 mm below bregma, or the location of lesion from impact. Brains
were then placed inside plastic molds, submerged in OCT and frozen over a methanol-dry
ice slurry. Following the embedding procedure, brains were sliced coronally into 15 um
thick sections and placed onto microscope slides. Slides were frozen at -80 °C prior to
immunostaining.
3.2.7 Immunostaining
Slides were rinsed thrice with PBS and incubated with blocking buffer (PBS, 3%
Donkey Serum, 0.3% Triton X-100, 0.1% Sodium Azide) for 1 hour at room temperature.
Primary antibody dilutions were prepared, added dropwise, and slides are incubated for
24 hours at 4 °C. Slides were washed thrice for 5 minutes in blocking buffer, prior to the
dropwise addition of secondary antibody. Slides were then covered to be protected from
light and left to sit at room temperature for 1.5 hours. Following secondary antibody
incubation, slides were washed thrice with blocking buffer and rinsed once with PBS.
DAPI solution was applied and left to sit for 5 minutes, before washing twice with PBS
and once with DDI water. Prolong Gold was applied dropwise over the center of each
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coronal section and cover slips were applied. Slides were stored at -80 °C until imaged
through confocal microscopy. Parameters used during confocal microscopy for 40x colocalization images for each respective antibody are provided here: LC3B (1.8%, 800 V)
and LAMP1 (1.0% 680V)
3.2.8 Statistical Analysis
All data are represented as mean ± standard deviation (SD) with N=3 for all
groups. Statistical analysis was performed using GraphPad Prism (version 9.3.1) and all
graphs were generated using this software. Prior to running comparative analysis, all data
was first analyzed for normality using the Shapiro-Wilk Test, and all data collected
passed this test. For examining comparisons of injury timeline to control, data was
analyzed using Two-way ANOVA with Dunnett’s multiple comparisons test for post hoc
analysis (#: CTRL vs Injury). For examining comparisons between injuries, data was
analyzed using Two-Way ANOVA with Tukey’s Honest Significantly Difference test for
post hoc analysis (&: CTRL vs Mild and #: MTBI vs DTBI).
3.3 Results
3.3.1 Gross Neuropathology
Gross pathological changes following TBI are a direct consequence of both the
mechanism and severity of primary impact. As such, examining differences in brain
pathology is imperative for establishing spectrums of injury amongst various types of
animal models. Additionally, these observations are useful for making comparisons to the
neuroanatomical changes observed in a clinical setting through imaging techniques,
including magnetic resonance imaging (MRI) and computed tomography imaging (CT).
Following perfusions, brains were imaged at 1, 3, and 7 days post injury to observe
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changes in gross pathology. These images were also used to evaluate the reproducibility
between impacts and compare brain lesions, or lack thereof, against previously developed
protocols. Impacts from the CCI model produced cortical lesions in the ipsilateral region
observed at each time point following impact (Figure 3.1.). Visible hemorrhaging
surrounding lesions was observed at 1 and 3 days post injury. Brain images following
MTBI presented with similar results, however, lesion size and depth was reduced when
compared with CCI at each time point. In contrast, no lesions were present in either
hemisphere following DTBI. However, slight hemorrhaging was observed throughout the
midline at 1 and 3 days post injury, and at the tentorium cerebelli, the space dividing the
cerebrum and cerebellum at 3 days time point. These results provide gross pathological
evidence for producing a spectrum of TBI variability with different injury mechanisms
and severities, through modifications from one impactor device.
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CTRL

CCI

MTBI

DTBI

1 Day
Post TBI

3 Days
Post TBI

7 Days
Post TBI

Figure 3.1. Schematic of experimental conditions and representative brain images
collected from each of the impact models at 1, 3 and 7 days post injury. Cortical lesions
were present at each time point following CCI impact. mTBI impacts produced similar
focal lesions and hemorrhaging but was less pronounced at 7 days post injury. Impacts
following dTBI impacts did not produce cortical lesions, and hemorrhaging was only
observed in the midline at days 1 and 3 post injury. CTRL: Control; CCI: traditional
controlled cortical impact; mTBI: mild impact with modified silicone tip; dTBI: diffuse
impact with protective helmet.
3.3.2 Injury severity and the mechanisms of cell death
Gross pathological differences suggest distinct shifts in molecular
pathophysiology, specifically regarding the spectrum of cell death. Thus, we investigated
changes in the mechanisms of cell death, including apoptosis and necrotic oncosis
(hereby referred to as oncosis), in the acute/subacute period following impact. Western
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blot analysis was used to observe changes in protein expression from α-II-spectrin
breakdown products (SBDPs). α-II-spectrin is a molecular scaffold protein involved in
the linkage between the plasma membrane and the cell’s cytoskeleton [77]. Following
damage to the cell, the protein is cleaved through two independent pathways including
calpain-mediated cleavage and caspase-mediated cleavage indicating changes in oncosis
and apoptosis, respectively. SBDPs correlate to total cell death (150 kDa), oncosis (145
kDa), and apoptosis (120 kDa) and were normalized to control.
Following severe CCI, we observed a significant increase in oncotic cell death,
which is consistent with previous pre-clinical CCI studies and clinical assessment of
severe TBI [77, 128]. Oncosis peaked at 3 days post injury and was present in each of the
four brain regions following impact (Figure 3.2.). In contrast, neither mild TBI model
presented with changes in oncotic cell death. Indeed, even with observable changes in
gross neuropathology, no significant changes in oncosis or apoptosis were observed
following MTBI. (Figure 3.3.). These results indicate a dramatic reduction in injury
severity, due to the softer tip and reduced depth, decreasing the molecular
pathophysiological consequences following TBI. However, following DTBI, apoptosis
was significantly increased in the cortex at each time point, and peaked at 3 days (Figure
3.4.). Additionally, total cell death peaked at 3 days in both the cortex and hippocampus,
coinciding with changes in apoptosis. Overall, these results suggest a shift in
pathophysiology due to the mechanism and severity of injury (Figure 3.5.).
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Figure 3.2. Western blot images and quantified data for SBDPs at 1, 3 and 7 days post
CCI. Oncosis was present at each time point following impact and peaked at 3 days post
injury in all four brain regions. No significant results were detected for total cell death or
apoptosis.
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Figure 3.5. Injury timeline of quantified data for SBDPs at 1, 3 and 7 days post injury.
Oncotic cell death and apoptotic cell death were only observed following impacts from
CCI and DTBI models, respectively. *: CCI vs Mild; #: MTBI vs DTBI
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3.3.3 Injury mechanism and apoptotic response
Due to the gross pathological changes following MTBI, we expected to see
evidence of either oncotic or apoptotic cell death. Thus, we further investigated changes
in apoptosis with the pro-apoptotic regulator, BAX. BAX plays a primary role in driving
mitochondrial membrane permeabilization, leading to apoptosis [68]. Interestingly, both
MTBI and DTBI resulted in increased BAX protein expression, confirming that apoptotic
cell death is in fact present following mild impact. BAX peaked at 3 days post injury in
the LC for both models, corresponding with increases in SBDP’s for DTBI (Figure 3.6.).
We also observed peak expression in the LH at 7 days following MTBI, indicating a
progression of secondary damage post impact (Figure 3.7.). Additionally, differences
between models were observed in the right hemisphere, providing additional evidence for
injury mechanism influencing pathophysiology.
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Figure 3.6. Western blot images and quantified data for BAX at 1, 3 and 7 days post mild
TBI. BAX peaked in the LC at 3 days for both MTBI and DTBI, but no changes were
observed following MTBI in the RC. DTBI data was averaged between left and right
hemispheres for the cortex and hippocampus (HC). *: CTRL vs Injury; #: MTBI vs DTBI.
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Figure 3.7. Western blot images and quantified data for BAX at 1, 3 and 7 days post mild
TBI. BAX peaked at 7 days in the LH following MTBI, suggesting a progression of
secondary injury. Additionally, we observed peak at 1 day in the HC following DTBI,
suggesting differences in the induction of apoptosis due to injury mechanism. DTBI data
was averaged between left and right hemispheres for the cortex and hippocampus (HC).
*CTRL vs Injury; #MTBI vs DTBI.
3.3.4. Impaired autophagic flux independent of mechanism and severity
Previous literature has demonstrated that autophagy is impaired in the
acute/subacute period following severe CCI [114, 115]. Autophagy is the major metabolic
pathway involved in cellular turnover, involved in the accumulation and degradation of
damaged or dysfunctional cellular components (Figure 3.8.) [89]. During periods of
cellular stress, autophagy is induced through two primary upstream regulatory processes,
including inhibition of the master regulatory protein complex, mechanistic target of
rapamycin (mTOR), as well as activation of AMP-activated protein kinase (AMPK) [92,
93]. Inhibiting mTOR complex 1 (mTORC1) allows for the translocation of transcription

factor EB (TFEB) into the nucleus, which acts as the key regulator in lysosomal
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biogenesis and autophagy [93, 94]. AMPK activates unc-51 like autophagy activating
kinase 1 (ULK1) complex, leading to the phosphorylation of Beclin1, a core subunit of
the PI3K complex, which initiates the production of autophagosomes [92, 95, 96].
Autophagy related genes 3 & 7 (ATG3 and ATG7) are involved in the covalent linkage
of phosphatidylethanolamine, converting LC3BI into LC3BII [97-99]. LC3BII, or
Microtubule-associated protein 1A/1B light chain 3B, is involved in the formation of the
autophagosome, specifically the elongation of the phagophore [97, 98]. During this
process, ubiquitin-binding protein P62 (also referred to as SQSTM1), selectively binds to
autophagic substrates tagging them for autophagic accumulation [100]. The
autophagosome continues to grow, and expands around the tagged targets, until
advancing into a mature autophagosome. The final steps in autophagy involve lysosomal
fusion with the autophagosome leading to lysosomal degradation, where nutrients can be
recycled for the specific needs of the cell [89].

Figure 3.8. Brief overview of the mechanisms of autophagy. Autophagy is a primary
mechanism of cellular turnover, involved in accumulating and degrading cellular
components. Autophagic substrates are recycled and reused for further synthesis by the
cell.
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Autophagic flux refers to the activity of autophagic degradation. Both
autophagosomes and their substrates are degraded by lysosomes following a complete
cycle of cellular turnover. Thus, corresponding increases in LC3BII and SQSTM1,
suggest autophagic flux is disrupted leading to an accumulation of cellular components in
the lysosome. Impaired autophagic flux has been reported previously following severe
injuries to the central nervous system and plays an active role in a variety of
neurodegenerative processes[114, 115, 124, 125]. Thus, understanding how injury
mechanism and severity influences autophagic flux could provide novel insight into
designing effective therapeutics for treating injury heterogeneity associated with TBI.
Following CCI, we observed a peak in LC3BII at 1 day post injury in the LC and
both hippocampi (Figure 3.9.). These results correspond to the initial increases in oncotic
cell death confirmed with SBDP’s. Autophagic flux was impaired at 1 day post injury in
the LH. However, we did not observe autophagic dysfunction in either the LC or RH.
These results were unexpected, as previous literature has shown a peak in autophagic
dysfunction in the ipsilateral cortex following less severe models of CCI. However, using
confocal microscopy, we did observe an increase in the co-localization of LC3BII with
LAMP1, just below the site of lesion, at 3 days post impact (Figure 3.10.). These results
suggest an accumulation of autophagosomes in the lysosome, indicating impaired
autophagic flux. We believe these observed differences are due to autophagosome
accumulation being localized to a small region beneath the impact site, when compared
with Western blot results for the entirety of the left cortex. Impacts from MTBI resulted
in impaired autophagic flux in the LC and LH, with peak accumulation at 3 days post
injury (Figure 3.11.). Results from the ipsilateral hemisphere coincided with peak
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increases in BAX following MTBI, suggesting impaired autophagic flux may be
associated with apoptotic cell death. However, due to the diffuse mild impact associated
with the MTBI model, we also observed autophagic dysfunction in the RH suggesting
impaired autophagic flux is associated with the spread of secondary injury following TBI.
Following DTBI, we observed significant increases in SQSTM1 at 3 days post injury in
the cortex following DTBI, corresponding with peak changes in apoptotic cell death
confirmed with both SBDP’s and BAX (Figure 3.12). However, we did not observe
corresponding increases in LC3BII in the cortex. In contrast, impaired autophagic flux
was observed at 1 day post injury in the hippocampus, coinciding with peak increases in
BAX protein expression. These results, coupled with changes in molecular
pathophysiology associated with cell death, suggest impaired autophagic flux plays a
primary role in the secondary consequences associated with TBI. Additionally,
autophagic biomarkers may be valuable targets for evaluating the efficacy of therapeutics
across a spectrum of injury heterogeneity.
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Figure 3.9. Western blot images and quantified data for autophagic markers, LC3BII and
SQSTM1 at 1, 3 and 7 days post CCI. LC3BII peaked at 1 day in the LC, LH, and RH.
Impaired autophagic flux was observed in the LH at 1 day post CCI.
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Figure 3.10. Images collected from confocal microscopy at 3 days post CCI in the
ipsilateral (left) and contralateral (right) cortex. We observed a dramatic increase in
autophagosomes (LC3B: Green) in the ipsilateral region, directly under the impact site.
Additionally, these autophagosomes were shown to be localized with lysosomes
(LAMP1: Red). In contrast, we did not observe any noticeable increases in either marker
in the contralateral region. These results suggest an accumulation of autophagic
substrates in the lysosome following CCI, indicating impaired autophagic flux.
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Figure 3.11. Western blot images and quantified data for autophagic markers, LC3BII and
SQSTM1 at 1, 3 and 7 days post MTBI. Impaired autophagic flux was observed in both
hippocampi and peaked at 3 days post MTBI. Additionally, LC3BII was increased in the
RC, with no observed increases in SQSTM1.
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Figure 3.12. Western blot images and quantified data for autophagic markers, LC3BII
and SQSTM1 at 1, 3 and 7 days post DTBI. SQSTM1 peaked at 3 days post DTBI in the
cortex, and autophagic dysfunction may be present in the hippocampus at 1 day post
injury.
3.4 Discussion and Limitations
Previous research has prioritized developing animal models, designed to simulate
clinical TBI, to investigate pathophysiological changes associated with injury. However,
evaluating individual models limits our scope of understanding how both injury
mechanism and severity generate the continuum of cognitive and behavioral deficits
observed clinically. Additionally, current challenges facing clinical trials and pre-clinical
translation are highly impacted by injury heterogeneity at the population level. Thus,
theranostic tools must be evaluated amongst of a spectrum of injuries to ensure adequate
targeting and efficacious drug delivery. Our results provide evidence for establishing
injury heterogeneity, with respect to both mechanism and severity, through modifications
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of the controlled cortical impact model. Following impacts, gross neuropathological
differences were observed between each injury, establishing three independent models
for investigating pathophysiology. Cortical lesions were present at each time point
following CCI, and a complete lack of lesion was observed following DTBI. However,
injuries following MTBI did result in cortical lesions at each time point and noticeable
hemorrhaging at days 1 and 3 post impact. These results are not reflective of the
pathology observed following mild TBI and did not coincide with observations from
previous methodology [43]. We believe these cortical lesions observed following MTBI
are due to damage to the underlying dura when using the larger trephine drill tip. Indeed,
through modifications to our current protocol, we produced an MTBI impact with no
cortical lesions or gross cortical hemorrhaging (Figure .12.). These results are promising,
suggesting these adjustments produced an injury more representative of mild injuries
seen clinically. Future work will assess how biochemical changes from this updated mild
injury, compares with our previous MTBI results. However, impacts from our MTBI
model did result in reduced pathological insults when compared to CCI and were
sufficient for producing significant differences in biochemical markers. Therefore, these
brains were used for the remainder of the study.
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CCI

MTBI

Updated MTBI

Figure 3.13. Comparison of brain images collected at 1 day post impact for CCI, MTBI,
and updated MTBI protocol. Due to the updated surgery protocol for MTBI, we were able
to produce impacts absent of gross neuropathological changes, suggesting injuries more
representative of mild TBI.
Previous pre-clinical and clinical TBI studies have discovered several differences
regarding mechanisms of cell death in response to injury severity [77, 83, 104, 115].
Results from these studies indicate an acute increase in oncotic cell death following
severe TBI and these changes may influence the functionality of other cellular
mechanisms. Due to the gross neuropathological changes observed following impact, we
investigated how injury heterogeneity influenced the mechanisms of cell death. Severe
CCI resulted in a dramatic increase in oncotic cell death, validated by SBDP’s, which has
been reported previously in pre-clinical studies and clinical assessment of severe TBI [77,
128]. While impacts from CCI are focal and are localized to the ipsilateral cortex, we

observed changes in oncosis at 1 day post injury, peaking at 3 days, in each of the four
brain regions. These results suggest the cascade of secondary damage associated with
severe TBI is rapidly progressing, limiting the window for therapeutic intervention. In
contrast, both MTBI and DTBI were absent of any significant changes in oncosis,
suggesting these injuries are more representative of the greater patient population.
However, SBDP’s for apoptosis reported significant increases in apoptotic cell death in
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the cortex following DTBI. Interestingly, apoptosis peaked at 3 days in the cortex, and
markers for total cell death also peaked at 3 days in both the cortex and hippocampus.
These corresponding peaks in oncotic and apoptotic cell death for CCI and DTBI
respectively, suggest that while injury mechanism and severity differ, the timeline for the
progression of cell damage remains unchanged. Additionally, we did not observe
significant changes in SBDP’s following MTBI, concluding that injury mechanism alone
influences the evolution of pathophysiology. However, due to the gross
neuropathological changes observed following MTBI, we expected to see corresponding
changes in either oncotic or apoptotic cell death in the acute period following injury.
Thus, we further investigated the mechanisms of apoptosis in both models of mild TBI
through examining changes in protein expression for the apoptotic regulator, BAX.
Interestingly, we did observe significant changes in the ipsilateral hemisphere following
MTBI, suggesting that mild injuries due in fact elicit an apoptotic response. We observed
a peak in BAX protein expression at 3 days in the LC, and at 7 days in the LH following
MTBI, providing evidence for the continuum of secondary damage following diffuse,
mild injury. Additionally, we observed a corresponding peak in BAX at 3 days post
DTBI in the cortex. This peak in apoptosis corresponds with previous results from
SBDP’s, and has been reported previously following closed head TBI [85]. Interestingly,
we observed a peak in BAX at 1 day in the hippocampus. We believe this early damage
in the hippocampus could be due to the diffuse impact acceleration of closed skull
impacts and could provide evidence for the acute cognitive deficits observed following
mild injury.
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Due to these corresponding changes between gross neuropathology and cellular
pathophysiology, we investigated how injury mechanism and severity influenced the
mechanisms of cell turnover, specifically autophagy. Previous literature has shown that
autophagic flux is impaired following severe CCI [114, 115]. Acutely following impact,
both LC3BII and SQSTM1 were upregulated in both the cortex and hippocampi, and
these results provide justification for the discrepancies associated with autophagic
intervention following TBI. Additionally, these studies concluded that autophagic
impairment may be directly correlated with dramatic increases in oncotic cell death
following severe injury. Therefore, we chose to examine autophagic flux acutely,
following impacts from each model to determine how differences in cell death coincided
with mechanistic changes in autophagy. Our results suggest that autophagic impairment
is present in all models of TBI, regardless of injury mechanism and severity. Following
CCI, we observed autophagic dysfunction in the LH. Both LC3BII and SQSTM1 peaked
at 1 day post impact, coinciding with the initial increase in oncotic cell death following
injury. Interestingly, we did not observe impaired autophagic flux in the LC, which had
been reported previously. However, these studies used CCI models which were less
severe, and we believe this lack of autophagic dysfunction could be due to the
overwhelming abundance of oncotic cell death localized in the cortex following impact.
Impaired autophagic flux was also present following MTBI, with peak changes at 3 days
post injury, corresponding with peak changes in BAX. Interestingly, we also observed
autophagic dysfunction in the RH, which correlates with the timeline of secondary
progression seen following CCI and DTBI. Additionally, impacts from our DTBI model
resulted in autophagy dysfunction in the hippocampus at 1 day post injury, which also
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coincided with peak changes in BAX protein expression. Therefore, both oncotic and
apoptotic cell death appear influenced by autophagic dysfunction.
Due to the plethora of secondary consequences experienced following TBI,
establishing mechanistic links in molecular pathophysiology may provide researchers
with unique upstream targets for therapeutic intervention. Previous literature has
identified that impaired autophagic dysfunction is due to lysosomal membrane
permeabilization (LMP) [114, 115]. LMP produces pores along the membrane of the
lysosome, allowing cathepsins and other degradative enzymes to escape, which have
shown to induce both apoptotic and oncotic cell death [116, 117]. Therefore, the upstream
link between each of these pathophysiological processes may be LMP. LMP is induced
through a variety of mechanisms, including increased production of reactive oxygen
species (ROS) [118]. Thus, developing therapeutic strategies for mitigating the
production of ROS, may mitigate LMP and lead to the physiological activation and
continuation of autophagy.
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CHAPTER 4: CONCLUSION AND FUTURE WORK
4.1 Conclusion
Due to the prevalence of mild TBI observed clinically, there is a critical need to
evaluate the pathophysiological changes associated with injury severity, in addition to the
outcomes influenced by impact mechanisms. Indeed, this research aimed to evaluate a
closed head injury model using an electromagnetic impact device to determine the
clinical translatability and the practicality of usage in producing repeated mild injuries.
Interestingly, we observed that the input parameters from our electromagnetic CCI device
were not correlated with outcome, specifically with respect to actual impact speed.
Indeed, the actual impact speeds were far lower than anticipated, which has a dramatic
effect on the direct comparison between pre-clinical models. We determined that the
actual impact speed was highly dependent on both input velocity and depth, where
regardless of input velocity, 9 mm and 15 mm impacts recorded the highest and lowest
impact speeds, respectively. Thus, these results raise concern for researchers using an
electromagnetic CCI device for producing diffuse, mild impacts and we suggest models
should be characterized to ensure results are interpreted based on the actual impact
conditions. Additionally, we investigated how impact speeds influenced pathophysiology,
through examining biomarkers associated with cell turnover, specifically autophagy. Our
results concluded that autophagic flux was impaired in the hippocampus, regardless of
impact speed, providing rationale for evaluating autophagic flux in a range of impact
severities and mechanisms.
Therefore, we investigated pathophysiological changes in multiple TBI animal
models, including one severe, focal impact and two diffuse, mild impacts. Ultimately,
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these impact models produced a spectrum of injuries, through modifications of a CCI
device. Following impacts, we observed distinct differences in gross neuropathology,
which corresponded with changes in the progression of cell death. Indeed, severe CCI
resulted in dramatic increases in oncotic cell death, which has been shown in both preclinical and clinical severe TBI. In contrast, mild models resulted in differences regarding
apoptotic response, suggesting injury mechanism alone shifts the progression of
pathophysiology. Interestingly, each of the three impact models resulted in impaired
autophagic flux, which coincided with changes in both oncotic and apoptotic cell death.
Thus, these results suggest that examining biomarkers associated with autophagy may
provide unique insight for evaluating the efficacy of potential therapeutics in a spectrum
of injury models. Additionally, these results provide evidence that the pathophysiological
mechanisms affiliated with TBI heterogeneity may be linked through common upstream
events, namely impaired autophagic flux and lysosomal dysfunction. Therefore,
therapeutic strategies designed to intervene in the amelioration of these consequences
may alleviate molecular dysfunction, thus alleviating cognitive and behavioral deficits.
4.2 Future Work
The primary goal of this work was to establish injury heterogeneity through
modifications in the CCI device and examine the differences and similarities in
biochemical response. While we were able to achieve significant differences between
severe and mild models, gross neuropathological changes following MTBI were more
severe than previously expected. Thus, our future work will consist of reproducing MTBI
injuries with our updated surgical protocol and examine secondary changes in molecular
pathophysiology as discussed previously. We believe that these new results will provide
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data that is more translatable to the mild injuries observed clinically and offer insight into
how damage to the dura following craniectomy influences biochemical response.
Additionally, this work only examined the pathophysiological differences associated with
injury mechanism and severity. However, impact frequency also plays a primary role in
the evolution of behavioral deficits observed clinically. Indeed, several studies have
shown that repeated mild injuries are linked to the progression of neurodegenerative
diseases. Thus, we are interested in determining how repeated closed head injuries
influence the progression of cell death and contributes to the progression of impaired
autophagic flux.
Additionally, due to the multitude of sequalae associated with TBI, establishing
mechanistic links in molecular pathophysiology may provide researchers with unique
upstream targets for therapeutic intervention. Previous literature has shown that impaired
autophagic dysfunction is due to lysosomal membrane permeabilization (LMP) [114,
115]. LMP is induced through increased ROS production and contributes to both

apoptotic and oncotic cell death [116-118]. Therefore, the upstream link between each of
these pathophysiological processes may be LMP. Thus, developing therapeutic strategies
for mitigating the production of ROS, may mitigate LMP and lead to the physiological
activation and continuation of autophagy. Our previous work has focused on
synthesizing, characterizing, and assessing the therapeutic efficacy of antioxidant
nanoparticles following TBI. These nanoparticles have shown to effectively scavenge
ROS, alleviate secondary pathophysiological damage, and ameliorate cognitive deficits
associated with moderate to severe TBI [129-132]. Thus, our future work will assess how
to improve the accumulation of these nanoparticles in less severe forms of injury,
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examine how they influence the activation of autophagy and determine whether they
provide an effect for ameliorating impaired autophagic flux.
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APPENDIX
A. SAS Code used for generating the fitted regression model for impact speed.
SAS Code:
data a; input x d v y; datalines; *Data excluded* proc print; run;
proc mixed method=type3; class d v; model y = d v d*v;
contrast 'D Lin' d -1 0 1;
contrast 'D Quad' d 1 -2 1;
contrast 'V Lin' v -1 0 1;
contrast 'V Quad' v 1 -2 1;
contrast 'D Lin * V Lin' d*v 1 0 -1 0 0 0 -1 0 1;
contrast 'D Lin * V Quad' d*v -1 2 -1 0 0 0 1 -2 1;
contrast 'D Quad * V Lin' d*v -1 0 1 2 0 -2 -1 0 1;
contrast 'D Quad * V Quad' d*v 1 -2 1 -2 4 -2 1 -2 1;
lsmeans d v d*v; run; proc sort; by d v;
proc means; by d v; var y; output out=b mean=ym;
proc plot; plot ym*v=d / hpos=40 vpos=15; run;
proc glm; model ym= d v d*d v*v d*v; run;
data b; do d=3 to 15 by 1; do v=2 to 4 by 0.1;
y= -1.1559 + 0.2595*d + 1.42028*v - 0.0111*d*d - 0.1694*v*v - 0.0286*d*v;
output; end; end; run; proc g3d; plot v*d=y; run; run;
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B. Multivariate implicit differentiation for obtaining the maximum impact speed.
𝒀𝒀 = −𝟏𝟏. 𝟏𝟏𝟏𝟏𝟏𝟏 + 𝟎𝟎. 𝟐𝟐𝟐𝟐𝟐𝟐 + 𝟏𝟏. 𝟒𝟒𝟒𝟒𝟒𝟒 − 𝟎𝟎. 𝟎𝟎𝟎𝟎𝟎𝟎𝒅𝒅𝟐𝟐 − 𝟎𝟎. 𝟏𝟏𝟏𝟏𝟏𝟏𝒗𝒗𝟐𝟐 − 𝟎𝟎. 𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎𝟎

Step 1. Set equation equal to zero.

−1.156 + 0.26𝑑𝑑 + 1.42𝑣𝑣 − 0.011𝑑𝑑2 − 0.169𝑣𝑣 2 − 0.029𝑑𝑑𝑑𝑑 − 𝑦𝑦 = 0

Step 2. Find partial derivatives.

𝜕𝜕𝜕𝜕
= 0.26 − 0.022𝑑𝑑 − 0.029𝑣𝑣
𝜕𝜕𝜕𝜕
𝝏𝝏𝝏𝝏

𝜕𝜕𝜕𝜕
= 1.42 − 0.338𝑣𝑣 − 0.029𝑑𝑑
𝑑𝑑𝑑𝑑

Step 3. Solve for v, when 𝝏𝝏𝝏𝝏 = 𝟎𝟎.

𝜕𝜕𝜕𝜕
= 0 = 1.42 − 0.338𝑣𝑣 − 0.029𝑑𝑑
𝜕𝜕𝜕𝜕

𝝏𝝏𝝏𝝏

𝑣𝑣 =

(1.42 − 0.029𝑑𝑑)
0.338

Step 4. Plug in v, when 𝝏𝝏𝝏𝝏 = 𝟎𝟎, and solve for d.

𝜕𝜕𝜕𝜕
0.029(1.42 − 0.029𝑑𝑑)
= 0 = 0.26 − 0.022𝑑𝑑 −
𝜕𝜕𝜕𝜕
0.338

Step 5. Plug in d, when

𝝏𝝏𝝏𝝏

𝝏𝝏𝝏𝝏

𝑑𝑑 = 7.08

= 𝟎𝟎, and solve for v.

𝜕𝜕𝜕𝜕
= 0 = 1.42 − 0.338𝑣𝑣 − 0.029(7.08)
𝑑𝑑𝑑𝑑
𝑣𝑣 = 3.59
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